Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Search

Page Path
HOME > Search
34 "Il Han Kim"
Filter
Filter
Article category
Keywords
More +
Publication year
More +
Authors
More +
Funded articles
More +
Original Articles
Hematologic malignancy
Higher Microbial Abundance and Diversity in Bronchus-Associated Lymphoid Tissue Lymphomas Than in Non-cancerous Lung Tissues
Jung Heon Kim, Jae Sik Kim, Noorie Choi, Jiwon Koh, Yoon Kyung Jeon, Ji Hyun Chang, Eung Soo Hwang, Il Han Kim
Cancer Res Treat. 2025;57(2):580-589.   Published online September 30, 2024
DOI: https://doi.org/10.4143/crt.2024.689
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
It is well known that the majority of the extranodal marginal zone lymphomas of mucosa-associated lymphoid tissues (MALT lymphomas) are associated with microbiota, e.g., gastric MALT lymphoma with Helicobacter pylori. In general, they are very sensitive to low-dose radiotherapy and chemotherapeutic agents. The microbiota profile is not clearly elucidated in bronchus-associated lymphoid tissue (BALT) lymphoma, a rare type of MALT lymphoma in the lung. Thus, this study aimed to clarify the intratumor microbiome in BALT lymphoma using the third-generation next-generation sequencing (NGS) method.
Materials and Methods
DNAs were extracted from 12 formalin-fixed paraffin-embedded (FFPE) tumor tissues obtained from BALT lymphoma patients diagnosed between 1990 and 2016. 16S rRNA gene was amplified by polymerase chain reaction. Amplicons were sequenced using a Nanopore platform. Next-generation sequencing analysis was performed to assess microbial profiles. For comparison, FFPE specimens from nine non-cancerous lung tissues were also analyzed.
Results
Specific bacterial families including Burkholderiaceae, Bacillaceae, and Microbacteriaceae were associated with BALT lymphoma by a linear discriminant analysis effect size approach. Although the number of specimens was limited, BALT lymphomas exhibited significantly higher microbial abundance and diversity with distinct microbial composition patterns and correlation networks than non-cancerous lung tissues.
Conclusion
This study provides the first insight into intratumor microbiome in BALT lymphoma using the third-generation NGS method. A distinct microbial composition suggests the presence of a unique tumor microenvironment of BALT lymphoma.
  • 1,473 View
  • 117 Download
Close layer
CNS cancer
Suggestions for Escaping the Dark Ages for Pediatric Diffuse Intrinsic Pontine Glioma Treated with Radiotherapy: Analysis of Prognostic Factors from the National Multicenter Study
Hyun Ju Kim, Joo Ho Lee, Youngkyong Kim, Do Hoon Lim, Shin-Hyung Park, Seung Do Ahn, In Ah Kim, Jung Ho Im, Jae Wook Chung, Joo-Young Kim, Il Han Kim, Hong In Yoon, Chang-Ok Suh
Cancer Res Treat. 2023;55(1):41-49.   Published online March 4, 2022
DOI: https://doi.org/10.4143/crt.2021.1514
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This multicenter retrospective study aimed to investigate clinical, radiologic, and treatment-related factors affecting survival in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) treated with radiotherapy.
Materials and Methods
Patients aged <30 years who underwent radiotherapy as an initial treatment for DIPG between 2000 and 2018 were included; patients who did not undergo magnetic resonance imaging at diagnosis and those with pathologically diagnosed grade I glioma were excluded. We examined medical records of 162 patients collected from 10 participating centers in Korea. The patients’ clinical, radiological, molecular, and histopathologic characteristics, and treatment responses were evaluated to identify the prognosticators for DIPG and estimate survival outcomes.
Results
The median follow-up period was 10.8 months (interquartile range, 7.5 to 18.1). The 1- and 2-year overall survival (OS) rates were 53.5% and 19.0%, respectively, with a median OS of 13.1 months. Long-term survival rate (≥ 2 years) was 16.7%, and median OS was 43.6 months. Age (< 10 years), poor performance status, treatment before 2010, and post-radiotherapy necrosis were independently associated with poor OS in multivariate analysis. In patients with increased post-radiotherapy necrosis, the median OS estimates were 13.3 months and 11.4 months with and without bevacizumab, respectively (p=0.138).
Conclusion
Therapeutic strategy for DIPG has remained unchanged over time, and the associated prognosis remains poor. Our findings suggest that appropriate efforts are needed to reduce the occurrence of post-radiotherapy necrosis. Further well-designed clinical trials are recommended to improve the poor prognosis observed in DIPG patients.

Citations

Citations to this article as recorded by  
  • An Investigation of the Effect of Nimotuzumab Combined with Radiation Therapy on Gliomas
    巍瀚 张
    Advances in Clinical Medicine.2025; 15(04): 3098.     CrossRef
  • Advancements in Image-Based Models for High-Grade Gliomas Might Be Accelerated
    Guido Frosina
    Cancers.2024; 16(8): 1566.     CrossRef
  • The relationship between imaging features, therapeutic response, and overall survival in pediatric diffuse intrinsic pontine glioma
    Xiaojun Yu, Mingyao Lai, Juan Li, Lichao Wang, Kunlin Ye, Dong Zhang, Qingjun Hu, Shaoqun Li, Xinpeng Hu, Qiong Wang, Mengjie Ma, Zeyu Xiao, Jiangfen Zhou, Changzheng Shi, Liangping Luo, Linbo Cai
    Neurosurgical Review.2024;[Epub]     CrossRef
  • Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma
    Lauren M. Arms, Ryan J. Duchatel, Evangeline R. Jackson, Pedro Garcia Sobrinho, Matthew D. Dun, Susan Hua
    Journal of Controlled Release.2024; 370: 835.     CrossRef
  • Pediatric diffuse intrinsic pontine glioma radiotherapy response prediction: MRI morphology and T2 intensity-based quantitative analyses
    Xiaojun Yu, Shaoqun Li, Wenfeng Mai, Xiaoyu Hua, Mengnan Sun, Mingyao Lai, Dong Zhang, Zeyu Xiao, Lichao Wang, Changzheng Shi, Liangping Luo, Linbo Cai
    European Radiology.2024; 34(12): 7962.     CrossRef
  • 6,289 View
  • 233 Download
  • 6 Web of Science
  • 5 Crossref
Close layer
The Role of Postoperative Radiotherapy in Intracranial Solitary Fibrous Tumor/Hemangiopericytoma: A Multi-institutional Retrospective Study (KROG 18-11)
Joo Ho Lee, Seung Hyuck Jeon, Chul-Kee Park, Sung-Hye Park, Hong In Yoon, Jong Hee Chang, Chang-Ok Suh, Su Jeong Kang, Do Hoon Lim, In Ah Kim, Jin Hee Kim, Jung Ho Im, Sung-Hwan Kim, Chan Woo Wee, Il Han Kim
Cancer Res Treat. 2022;54(1):65-74.   Published online March 24, 2021
DOI: https://doi.org/10.4143/crt.2021.142
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to evaluate the role of postoperative radiotherapy (PORT) in intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC).
Materials and Methods
A total of 133 patients with histologically confirmed HPC were included from eight institutions. Gross total resection (GTR) and subtotal resection (STR) were performed in 86 and 47 patients, respectively. PORT was performed in 85 patients (64%). The prognostic effects of sex, age, performance, World Health Organization (WHO) grade, location, size, Ki-67, surgical extent, and PORT on local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) were estimated by univariate and multivariate analyses.
Results
The 10-year PFS, and OS rates were 45%, and 71%, respectively. The multivariate analysis suggested that PORT significantly improved LC (p < 0.001) and PFS (p < 0.001). The PFS benefit of PORT was maintained in the subgroup of GTR (p=0.001), WHO grade II (p=0.001), or STR (p < 0.001). In the favorable subgroup of GTR and WHO grade II, PORT was also significantly related to better PFS (p=0.028). WHO grade III was significantly associated with poor DMFS (p=0.029). In the PORT subgroup, the 0-0.5 cm margin of the target volume showed an inferior LC to a large margin with 1.0-2.0 cm (p=0.021). Time-dependent Cox proportion analysis showed that distant failures were significantly associated with poor OS (p=0.003).
Conclusion
This multicenter study supports the role of PORT in disease control of intracranial SFT/HPC, irrespective of the surgical extent and grade. For LC, PORT should enclose the tumor bed with sufficient margin.

Citations

Citations to this article as recorded by  
  • The role of radiotherapy in intracranial hemangiopericytoma/solitary fibrous tumors
    Nuri Kaydıhan, Gözde Yazıcı, Petek Erpolat, Serra Kamer, Burak Erdemci, Emine Canyılmaz, Beste Melek Atasoy, Dicle Aslan, Ela Delikgöz Soykut, Enis Özyar, Fatih Demircioğlu, Fazilet Öner Dinçbaş, Meltem Kirli Bolukbas, Ramazan Aksu, Selvi Tabak Dinçer, Ya
    Strahlentherapie und Onkologie.2025; 201(4): 431.     CrossRef
  • Does Adjuvant Radiotherapy Enhance Survival in Intracranial Solitary Fibrous Tumor Patients?
    Sakhr Alshwayyat, Haya Kamal, Tala Abdulsalam Alshwayyat, Mustafa Alshwayyat, Mesk Alkhatib, Ayah Erjan
    World Neurosurgery.2025; 194: 123545.     CrossRef
  • Application and effect evaluation of microsurgical resection combined with intensity-modulated radiation therapy in the treatment of intracranial solitary fibrous tumor/hemangiopericytoma
    Jingcheng Jiang, Xiaoqin Qu, Han Wang, Chao Zhang, Qingshan Deng, Xiaoping Xu, Jun Qiu, Lihua Qu, Yong Yi
    Medicine.2025; 104(6): e41336.     CrossRef
  • Mesenchymal Nonmeningothelial Tumors of the CNS: Evolving Molecular Landscape and Implications for Neuroradiologists
    Neetu Soni, Manish Ora, Denes Szekeres, Girish Bathla, Amit Desai, Vivek Gupta, Aparna Singhal, Amit Agarwal
    American Journal of Neuroradiology.2025; 46(5): 868.     CrossRef
  • Meningeal malignant solitary fibrous tumor with multiple recurrence, extracranial extension, cervical lymph node metastases: case report and review of the literature
    Rong He, Peng Zhong, Juntao Hu, Guangkuo Guo, He Xiao, Lin Lei, Yun Liu, Mingying Geng, Jungang Ma
    Discover Oncology.2025;[Epub]     CrossRef
  • Development of an MRI‐Based Comprehensive Model Fusing Clinical, Radiomics and Deep Learning Models for Preoperative Histological Stratification in Intracranial Solitary Fibrous Tumor
    Xiaohong Liang, Kaiqiang Tang, Xiaoai Ke, Jian Jiang, Shenglin Li, Caiqiang Xue, Juan Deng, Xianwang Liu, Cheng Yan, Mingzi Gao, Junlin Zhou, Liqin Zhao
    Journal of Magnetic Resonance Imaging.2024; 60(2): 523.     CrossRef
  • Meningeal Solitary Fibrous Tumor: A Single-Center Retrospective Cohort Study
    Siyer Roohani, Yasemin Alberti, Maximilian Mirwald, Felix Ehret, Carmen Stromberger, Soleiman Fabris Roohani, Katja Bender, Anne Flörcken, Sven Märdian, Daniel Zips, David Kaul, Manish Charan
    Sarcoma.2024; 2024: 1.     CrossRef
  • Repeated Radiation Therapy of Recurrent Solitary Fibrous Tumors of the Brain: A Medical Case History Over 20 Years
    Anna Carla Piccardo, Sabrina Gurdschinski, Sybille Spieker, Christof Renner, Piotr Czapiewski, Markus Wösle, I. Frank Ciernik
    Advances in Radiation Oncology.2024; 9(4): 101426.     CrossRef
  • Intracranial solitary fibrous tumors: Clinical, radiological, and histopathological insights along with review of literature
    Adil Aziz Khan, Sana Ahuja, Dipanker Singh Mankotia, Sufian Zaheer
    Pathology - Research and Practice.2024; 260: 155456.     CrossRef
  • Central nervous system solitary fibrous tumors: Case series in accordance with the WHO 2021 reclassification. Framework for patient surveillance
    V. Matthijs, R. Beckers, C. Vanden Broecke, F. Dedeurwaerdere, J. Van Dorpe, D. Vanhauwaert, G. Hallaert
    Acta Neurochirurgica.2024;[Epub]     CrossRef
  • Recurrence of Solitary Fibrous Tumor in the Spinal Cord Following Gross Total and Subtotal Resection: A Case Report of Recurrence 19 Years of Post-total Resection and Systematic Literature Review
    Satoka SHIDOH, Kazutoshi HIDA, Yoshitaka ODA, Toru SASAMORI, Prabin SHRESTHA, Jangbo LEE, Satoshi YAMAGUCHI
    NMC Case Report Journal.2024; 11: 297.     CrossRef
  • The Role of Radical Radiotherapy in Sinonasal Myopericytoma: A Case Report and Literature Overview
    Anna Merlotti, Stefania Martini, Riccardo Vigna Taglianti, Alessia Reali, Giuseppe Signorini, Silvana Parisi, Francesca De Felice
    EMJ Oncology.2023;[Epub]     CrossRef
  • Intracranial Solitary Fibrous Tumour Management: A French Multicentre Retrospective Study
    Marine Lottin, Alexandre Escande, Luc Bauchet, Marie Albert-Thananayagam, Maël Barthoulot, Matthieu Peyre, Mathieu Boone, Sonia Zouaoui, Jacques Guyotat, Guillaume Penchet, Johan Pallud, Henry Dufour, Evelyne Emery, Michel Lefranc, Sébastien Freppel, Houm
    Cancers.2023; 15(3): 704.     CrossRef
  • Solitary fibrous tumor of the central nervous system invading and penetrating the skull: A case report
    Qiyan Lin, Jiabin Zhu, Xiaofeng Zhang
    Oncology Letters.2023;[Epub]     CrossRef
  • Impact of extent of resection and postoperative radiotherapy on survival outcomes in intracranial solitary fibrous tumors: a systematic review and meta-analysis
    Sae Min Kwon, Min Kyun Na, Kyu-Sun Choi, Tae Ho Lim, Hyungoo Shin, Juncheol Lee, Heekyung Lee, Wonhee Kim, Youngsuk Cho, Jae Guk Kim, Chiwon Ahn, Bo-Hyoung Jang
    Neurosurgical Review.2023;[Epub]     CrossRef
  • Radiotherapy for rare primary brain tumors
    E. Mesny, P. Lesueur
    Cancer/Radiothérapie.2023; 27(6-7): 599.     CrossRef
  • Complete Resection of a Torcular Herophili Hemangiopericytoma without Sinus Reconstruction: A Case Report and Review of the Literature
    Salah-Edine Safi, Julie Godfrain, Herbert Rooijakkers, Frederic Collignon, Mario Ganau
    Case Reports in Surgery.2023; 2023: 1.     CrossRef
  • Surgical Management of Craniospinal Axis Solitary Fibrous Tumors: A Single-Institution Case Series and Comprehensive Review of the Literature
    Anthony J. Piscopo, A. J. Chowdhury, Nahom Teferi, Sarah Lee, Meron Challa, Michael Petronek, Kathryn Eschbacher, Girish Bathla, John M. Buatti, Patrick Hitchon
    Neurosurgery.2023;[Epub]     CrossRef
  • Clinical Features, Management, and Prognostic Factors of Intracranial Solitary Fibrous Tumor
    Jingdian Liu, Sisi Wu, Kai Zhao, Junwen Wang, Kai Shu, Ting Lei
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Toward Better Understanding and Management of Solitary Fibrous Tumor
    Karineh Kazazian, Elizabeth G. Demicco, Marc de Perrot, Dirk Strauss, Carol J. Swallow
    Surgical Oncology Clinics of North America.2022; 31(3): 459.     CrossRef
  • Effect of Different Treatments for Intracranial Solitary Fibrous Tumors: Retrospective Analysis of 31 Patients
    Qinghua Li, Wenshuai Deng, Peng Sun
    World Neurosurgery.2022; 166: e60.     CrossRef
  • Sixteen-Year Follow-Up in a Cavernous Sinus Hemangiopericytoma: Improved Outcomes over Radiotherapy Advances
    Beatrice Detti, Lilia Bardoscia, Antonio Rosario Pisani, Salvatore Cozzi, Manuele Roghi, Paolo Mammucci, Angela Sardaro
    Brain Sciences.2022; 12(9): 1209.     CrossRef
  • Solitary Fibrous Tumor of the Jugular Foramen: A Case Report and Review of the Histopathologic Classification
    Mallory Raymond, Philip Ryan Elvis, Tiffany Baker, William Alexander Vandergrift, Theodore McRackan
    Otology & Neurotology.2022; 43(10): e1208.     CrossRef
  • A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons
    Javier Martin-Broto, Jose L. Mondaza-Hernandez, David S. Moura, Nadia Hindi
    Cancers.2021; 13(12): 2913.     CrossRef
  • Intradural Extramedullary Solitary Fibrous Tumor of the Thoracic Spinal Cord
    Zachary T Olmsted, Joanna Tabor, Omer Doron, Hossein Hosseini, Daniel Schneider, Ross Green, Samuel J Wahl, Daniel M Scuibba, Randy S D'Amico
    Cureus.2021;[Epub]     CrossRef
  • 9,468 View
  • 362 Download
  • 24 Web of Science
  • 25 Crossref
Close layer
Long-Term Outcomes and Sequelae Analysis of Intracranial Germinoma: Need to Reduce the Extended-Field Radiotherapy Volume and Dose to Minimize Late Sequelae
Joo Ho Lee, Keun-Yong Eom, Ji Hoon Phi, Chul-Kee Park, Seung Ki Kim, Byung-Kyu Cho, Tae Min Kim, Dae Seog Heo, Kyung Taek Hong, Jung Yoon Choi, Hyoung Jin Kang, Hee Young Shin, Seung Hong Choi, Soon Tae Lee, Sung Hye Park, Kyu-Chang Wang, Il Han Kim
Cancer Res Treat. 2021;53(4):983-990.   Published online January 13, 2021
DOI: https://doi.org/10.4143/crt.2020.1052
AbstractAbstract PDFPubReaderePub
Purpose
We aimed to refine the radiotherapy (RT) volume and dose for intracranial germinoma considering recurrences and long-term toxicities.
Materials and Methods
Total 189 patients with intracranial germinoma were treated with RT alone (n=50) and RT with upfront chemotherapy (CRT) (n=139). All cases were confirmed histologically. RT fields comprised the extended-field and involved-field only for primary site. The extended-field, including craniospinal, whole brain (WB), and whole ventricle (WV) for cranial field, is followed by involved-field boost. The median follow-up duration was 115 months.
Results
The relapses developed in 13 patients (6.9%). For the extended-field, cranial RT dose down to 18 Gy exhibited no cranial recurrence in 34 patients. In CRT, 74 patients (56.5%) showed complete response to chemotherapy and no involved-field recurrence with low-dose RT of 30 Gy. WV RT with chemotherapy for the basal ganglia or thalamus germinoma showed no recurrence. Secondary malignancy developed in 10 patients (5.3%) with a latency of 20 years (range, 4 to 26 years) and caused mortalities in six. WB or craniospinal field rather than WV or involved-field significantly increased the rate of hormone deficiencies, and secondary malignancy. RT dose for extended-field correlated significantly with the rate of hormone deficiencies, secondary malignancy, and neurocognitive dysfunction.
Conclusion
De-intensifying extended-field rather than involved-field or total scheme of RT will be critical to decrease the late toxicities. Upfront chemotherapy could be beneficial for the patients with complete response to minimize the RT dose down to 30 Gy. Prospective trials focused on de-intensification of the extended-field RT are warranted.

Citations

Citations to this article as recorded by  
  • Optimal treatment approach for intracranial germinoma: a systematic review and meta-analysis
    Zhirui Zhou, Jiabing Liu, Qi Yue, Lingxiao Chen, Xiwei Zhang, Xin Lin, Lin Zheng, Enmin Wang, Yang Wang, Ying Mao
    BMC Cancer.2025;[Epub]     CrossRef
  • Distribution and failure patterns of primary central nervous system lymphoma related to the hippocampus: implications for hippocampal avoidance irradiation
    Hyejo Ryu, Xue Li, Tae Hoon Lee, Tae Min Kim, Seung Hong Choi, Chul-Kee Park, Soon Tae Lee, Sung-Hye Park, Jae-Kyung Won, Bum-Sup Jang, Il Han Kim, Joo Ho Lee
    Journal of Neuro-Oncology.2025; 173(1): 95.     CrossRef
  • NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors
    Eric Eunshik Kim, Chul-Kee Park, Seung-Ki Kim, Ji Hoon Phi, Sun Ha Paek, Jung Yoon Choi, Hyoung Jin Kang, Joo Ho Lee, Jae Kyung Won, Hongseok Yun, Sung-Hye Park
    Acta Neuropathologica Communications.2024;[Epub]     CrossRef
  • Clinical significance of cerebral microbleeds in patients with germinoma who underwent long-term follow-up
    Masayuki Kanamori, Shunji Mugikura, Osamu Iizuka, Naoko Mori, Yoshiteru Shimoda, Ichiyo Shibahara, Rei Umezawa, Keiichi Jingu, Ryuta Saito, Yukihiko Sonoda, Toshihiro Kumabe, Kyoko Suzuki, Hidenori Endo
    Journal of Neuro-Oncology.2024; 170(1): 173.     CrossRef
  • Excluding prepontine cistern from whole ventricle radiotherapy target volume in localized germinoma
    Hyejo Ryu, Joo Ho Lee
    Radiation Oncology Journal.2023; 41(1): 48.     CrossRef
  • Intracranial Germinomas: Diagnosis, Pathogenesis, Clinical Presentation, and Management
    Natalia Kremenevski, Michael Buchfelder, Nirjhar Hore
    Current Oncology Reports.2023; 25(7): 765.     CrossRef
  • Proton therapy for pediatric diencephalic tumors
    Adam J. Grippin, Susan L. McGovern
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Intracranial Germinoma—Association between Delayed Diagnosis, Altered Clinical Manifestations, and Prognosis
    Iwona Jabłońska, Marcin Goławski, Elżbieta Nowicka, Katarzyna Drosik-Rutowicz, Anna Trybus, Rafał Tarnawski, Marcin Miszczyk
    Cancers.2023; 15(10): 2789.     CrossRef
  • Outcomes of intracranial germinoma—A retrospective multinational Asian study on effect of clinical presentation and differential treatment strategies
    Kyung-Nam Koh, Ru Xin Wong, Dong-Eun Lee, Jung Woo Han, Hwa Kyung Byun, Hong In Yoon, Dong-Seok Kim, Chuhl Joo Lyu, Hyoung Jin Kang, Kyung Taek Hong, Joo Ho Lee, Il Han Kim, Ji Hoon Phi, Seung-Ki Kim, Tai-Tong Wong, Hsin-Lun Lee, I-Chun Lai, Yu-Mei Kang,
    Neuro-Oncology.2022; 24(8): 1389.     CrossRef
  • Photon versus proton whole ventricular radiotherapy for non‐germinomatous germ cell tumors: A report from the Children's Oncology Group
    David Y. Mak, Zain Siddiqui, Zhihui Amy Liu, Hitesh Dama, Shannon M. MacDonald, Shengjie Wu, Erin S. Murphy, Matthew D. Hall, Victor Malkov, Arzu Onar‐Thomas, Sameera Ahmed, Girish Dhall, Derek S. Tsang
    Pediatric Blood & Cancer.2022;[Epub]     CrossRef
  • Factors Influencing Craniospinal Relapse of Intracranial Germinoma After Complete Remission
    Takao Tsurubuchi, Kei Hara, Shingo Takano, Ai Muroi, Hiroko Fukushima, Masashi Mizumoto, Noriaki Sakamoto, Masahide Matsuda, Hiroyoshi Akutsu, Hideyuki Sakurai, Eiichi Ishikawa
    World Neurosurgery.2022; 166: e325.     CrossRef
  • Molecular Pathology and Targeted Therapies for Personalized Management of Central Nervous System Germinoma
    Cristina Ilcus, Horatiu Silaghi, Carmen Emanuela Georgescu, Carmen Georgiu, Anca Ileana Ciurea, Simona Delia Nicoara, Cristina Alina Silaghi
    Journal of Personalized Medicine.2021; 11(7): 661.     CrossRef
  • 11,462 View
  • 361 Download
  • 13 Web of Science
  • 12 Crossref
Close layer
Interim Tumor Progression and Volumetric Changes of Surgical Cavities during the Surgery-to-Radiotherapy Interval in Anaplastic Gliomas: Implications for Additional Pre-radiotherapy Magnetic Resonance Imaging
Chan Woo Wee, Il Han Kim, Chul-Kee Park, Jin Wook Kim
Cancer Res Treat. 2020;52(2):524-529.   Published online October 31, 2019
DOI: https://doi.org/10.4143/crt.2019.520
AbstractAbstract PDFPubReaderePub
Purpose
This study was designed to investigate the incidence of interim disease progression (IPD) and volumetric changes of the surgical cavity (SC) during the surgery-to-radiotherapy interval (SRI), and eventually assess the value of magnetic resonance imaging (MRI) at the time of radiotherapy (RT) planning in newly diagnosed anaplastic gliomas.
Materials and Methods
Among 195 anaplastic glioma patients who underwent RT, 121 were evaluable with two separate MRIs during SRI. The presence of IPD was determined using the updated Response Assessment in Neuro-Oncology size criteria. In 84 patients who underwent surgical resection, each SC was contoured by a radiation oncologist and the volumetric changes of the SCs were calculated between the two separate MRIs. Daily rate of change in the SC volume was calculated assuming an exponential and linear change.
Results
Five of 121 patients (4.13%) demonstrated IPD during SRI, and the incidence was significantly higher in patients undergoing biopsy (vs. surgical resection, 12.9% vs. 1.1%, p=0.015) and in patients with remnant contrast-enhancing tumor after surgery (15.8 vs. 2.0%, p=0.027). The mean daily rate of absolute change in SC was 1.06% (95% confidence interval [CI], 0.89 to 1.23) and 0.89% (95% CI, 0.77 to 1.02) according to the exponential and linear model, respectively. The expected mean volumetric change at 2 weeks were 16.64% (95% CI, 13.77 to 19.52) and 12.51% (95% CI, 10.77 to 14.26), respectively.
Conclusion
IPD during the SRI is rare in surgically resected anaplastic gliomas. However, pre-RT MRI is essential for accurate RT-target delineation and disease evaluation for patients initiating RT beyond postoperative 2 weeks and undergoing biopsy, respectively.

Citations

Citations to this article as recorded by  
  • Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma—an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial
    Stefan Dietzsch, Annett Braesigk, Clemens Seidel, Julia Remmele, Ralf Kitzing, Tina Schlender, Martin Mynarek, Dirk Geismar, Karolina Jablonska, Rudolf Schwarz, Montserrat Pazos, Damien C. Weber, Silke Frick, Kristin Gurtner, Christiane Matuschek, Semi Be
    Strahlentherapie und Onkologie.2022; 198(3): 282.     CrossRef
  • Effect of 3D Slicer Preoperative Planning and Intraoperative Guidance with Mobile Phone Virtual Reality Technology on Brain Glioma Surgery
    Jun Liu, Xiaodong Li, Xueping Leng, Bo Zhong, Yanhong Liu, Liang Liu, Mohammad Farukh Hashmi
    Contrast Media & Molecular Imaging.2022;[Epub]     CrossRef
  • 5,823 View
  • 165 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
The Feasibility of Spinal Stereotactic Radiosurgery for Spinal Metastasis with Epidural Cord Compression
Yi-Jun Kim, Jin Ho Kim, Kyubo Kim, Hak Jae Kim, Eui Kyu Chie, Kyung Hwan Shin, Hong-Gyun Wu, Il Han Kim
Cancer Res Treat. 2019;51(4):1324-1335.   Published online January 29, 2019
DOI: https://doi.org/10.4143/crt.2018.653
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to investigate the effectiveness and safety of spinal stereotactic radiosurgery (SRS) in treating spinal metastasis with epidural spinal cord compression (ESCC).
Materials and Methods
During 2013-2016, 149 regions of spinal metastasis in 105 patients treated with singlefraction (12-24 Gy) spinal SRS were reviewed. Cord compression of Bilsky grade 2 (with visible cerebrospinal fluid [CSF]) or 3 (no visible CSF) was defined as ESCC. Local progression (LP) and vertebral compression fracture (VCF) rates after SRS were evaluated using multivariate competing-risk regression analysis.
Results
The 1-year cumulative incidences of LP for Bilsky grades 0 (n=80), 1 (n=39), 2 (n=21), and 3 (n=9) were 3.0%, 8.4%, 0%, and 24.9%, respectively. Bilsky grade 2 ESCC did not significantly increase the LP rate (no LP for grade 2). The 1-year cumulative incidences of VCF for Bilsky grades 0, 1, 2, and 3 were 6.6%, 5.2%, 17.1%, and 12.1%, respectively. ESCC may increase VCF risk (subhazard ratio [SHR] for grade 2, 5.368; p=0.035; SHR for grade 3, 2.215; p=0.460). Complete or partial pain response rates after SRS were 79%, 78%, 53%, and 63% for Bilsky grades 0, 1, 2, and 3, respectively (p=0.008). No neurotoxicity of grade ≥ 3 was observed.
Conclusion
Spinal SRS for spinal metastasis with Bilsky grade 2 ESCC did not increase the LP rate, was not associated with severe neurotoxicity, and showed moderate VCF and pain response rates. Bilsky grade 3 had a high LP rate.

Citations

Citations to this article as recorded by  
  • Palliative stereotactic body radiotherapy for spinal and non-spinal bone metastases: combining tradition and innovation
    Kei Ito, Naoki Nakamura
    International Journal of Clinical Oncology.2025;[Epub]     CrossRef
  • Efficacy and safety of SBRT for spine metastases: A systematic review and meta-analysis for preparation of an ESTRO practice guideline
    R.S. Guninski, F. Cuccia, F. Alongi, N. Andratschke, C. Belka, D. Bellut, M. Dahele, M. Josipovic, T.E. Kroese, P. Mancosu, G. Minniti, M. Niyazi, U Ricardi, P. Munck af Rosenschold, A. Sahgal, Y. Tsang, W.F.A.R. Verbakel, M. Guckenberger
    Radiotherapy and Oncology.2024; 190: 109969.     CrossRef
  • Metastatic Spinal Lesion with Minimal Epidural Compression: Surgical Treatment or Stereotactic Radiotherapy?
    O. I. Kit, D. E. Zakondyrin, A. A. Grin, E. E. Rostorguev, Y. V. Przhedetskiy, P. G. Sakun, V. I. Voshedskii, B. V. Matevosian, T. S. Shepelya
    Creative surgery and oncology.2024; 14(2): 127.     CrossRef
  • Surgical Interventions Following Radiotherapy in Spinal Metastases with Intermediate Instability: A Risk Factor Analysis: The Korean Society of Spinal Tumor Multicenter Study (KSST 2022-02)
    Se-Jun Park, Jin Ho Kim, Yong Chan Ahn, Woong Sub Koom, Hwa Kyung Byun, Young-Hoon Kim, Sang-Il Kim, Dong-Ho Kang
    Cancers.2024; 16(14): 2554.     CrossRef
  • Development of a novel 12-point grading system for evaluating epidural spinal cord compression and its clinical implications
    Xuyong Cao, Weihao Jiang, Xiongwei Zhao, Haikuan Yu, Mingxing Lei, Yuncen Cao, Xiuyun Su, Yaosheng Liu
    The Spine Journal.2023; 23(12): 1858.     CrossRef
  • Efficacy of Total En Bloc Spondylectomy versus Stereotactic Ablative Radiotherapy for Single Spinal Metastasis
    Dong-Ho Kang, Wooseok Lee, Bong-Soon Chang, Hyoungmin Kim, Sam Yeol Chang, Seong Hwa Hong, Jin Ho Kim, Hee Jung Son
    Cancers.2023; 15(23): 5518.     CrossRef
  • Radiomic modeling to predict risk of vertebral compression fracture after stereotactic body radiation therapy for spinal metastases
    Chengcheng Gui, Xuguang Chen, Khadija Sheikh, Liza Mathews, Sheng-Fu L. Lo, Junghoon Lee, Majid A. Khan, Daniel M. Sciubba, Kristin J. Redmond
    Journal of Neurosurgery: Spine.2022; 36(2): 294.     CrossRef
  • Stereotactic body radiotherapy for spinal metastases: a review
    Lanlan Guo, Lixin Ke, Ziyi Zeng, Chuanping Yuan, Ziwei Wu, Lei Chen, Lixia Lu
    Medical Oncology.2022;[Epub]     CrossRef
  • Treatment of Metastatic Spinal Disease; what the Radiologist needs to know
    Stephen Supple, Shahjehan Ahmad, Santhosh Gaddikeri, Miral D. Jhaveri
    The British Journal of Radiology.2022;[Epub]     CrossRef
  • Spinal metastases 2021: a review of the current state of the art and future directions
    Daniel M. Sciubba, Zach Pennington, Matthew W. Colman, C. Rory Goodwin, Ilya Laufer, Joshua C. Patt, Kristin J. Redmond, Philip Saylor, John H. Shin, Joseph H. Schwab, Andrew J. Schoenfeld
    The Spine Journal.2021; 21(9): 1414.     CrossRef
  • An updated algorithm for the treatment of spinal metastasis
    Kawngwoo Park, Seong Son, Sang Gu Lee, En Kyung Cho, Hee Kyung Ahn, In Keun Park, Sun Jin Sym, Young Saing Kim
    Journal of the Korean Society of Stereotactic and Functional Neurosurgery.2021; 17(2): 70.     CrossRef
  • Separation surgery for metastatic epidural spinal cord compression: A qualitative review
    Giuseppe Di Perna, Fabio Cofano, Cristina Mantovani, Serena Badellino, Nicola Marengo, Marco Ajello, Ludovico Maria Comite, Giuseppe Palmieri, Fulvio Tartara, Francesco Zenga, Umberto Ricardi, Diego Garbossa
    Journal of Bone Oncology.2020; 25: 100320.     CrossRef
  • Multidisciplinary management of metastatic spine disease: initial symptom-directed management
    Jeremy M Steinberger, Frank Yuk, Amish H Doshi, Sheryl Green, Isabelle M Germano
    Neuro-Oncology Practice.2020; 7(Supplement): i33.     CrossRef
  • 10,277 View
  • 232 Download
  • 14 Web of Science
  • 13 Crossref
Close layer
Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro
Hyeon Kang Koh, Soo Yeon Seo, Jin Ho Kim, Hak Jae Kim, Eui Kyu Chie, Seung-Ki Kim, Il Han Kim
Cancer Res Treat. 2019;51(2):696-705.   Published online August 13, 2018
DOI: https://doi.org/10.4143/crt.2018.249
AbstractAbstract PDFPubReaderePub
Purpose
Glioblastoma, the most common brain tumor in adults, has poor prognosis. The purpose of this study was to determine the effect of disulfiram (DSF), an aldehyde dehydrogenase inhibitor, on in vitro radiosensitivity of glioblastoma cells with different methylation status of O6-methylguanine-DNA methyltransferase (MGMT) promoter and the underlying mechanism of such effect.
Materials and Methods
Five human glioblastoma cells (U138MG, T98G, U251MG, U87MG, and U373MG) and one normal human astrocyte (NHA) cell were cultured and treated with DSF or 6MV X-rays (0, 2, 4, 6, and 8 Gy). For combined treatment, cells were treated with DSF before irradiation. Surviving fractions fit from cell survival based on colony forming ability. Apoptosis, DNA damage repair, and cell cycle distributionwere assayed bywestern blot for cleaved caspase-3, γH2AX staining, and flow cytometry, respectively.
Results
DSF induced radiosensitization in most of the glioblastoma cells, especially, in the cells with radioresistance as wildtype unmethylated promoter (MGMT-wt), but did not in normal NHA cell. DSF augmented or induced cleavage of caspase-3 in all cells after irradiation. DSF inhibited repair of radiation-induced DNA damage in MGMT-wt cells, but not in cells with methylated MGMT promoter. DSF abrogated radiation-induced G2/M arrest in T98G and U251MG cells.
Conclusion
Radiosensitivity of glioblastoma cells were preferentially enhanced by pre-irradiation DSF treatment compared to normal cell, especially radioresistant cells such as MGMT-wt cells. Induction of apoptosis or inhibition of DNA damage repair may underlie DSF-induced radiosensitization. Clinical benefit of combining DSF with radiotherapy should be investigated in the future.

Citations

Citations to this article as recorded by  
  • The role of KDM4A‐mediated histone methylation on temozolomide resistance in glioma cells through the HUWE1/ROCK2 axis
    Xi‐Xi Li, Jia‐Kun Xu, Wei‐Jie Su, Hong‐Lin Wu, Kun Zhao, Chang‐Ming Zhang, Xiang‐Kun Chen, Li‐Xuan Yang
    The Kaohsiung Journal of Medical Sciences.2024; 40(2): 161.     CrossRef
  • Glioblastoma Therapy: Past, Present and Future
    Elena Obrador, Paz Moreno-Murciano, María Oriol-Caballo, Rafael López-Blanch, Begoña Pineda, Julia Gutiérrez-Arroyo, Alba Loras, Luis Gonzalez-Bonet, Conrado Martinez-Cadenas, José Estrela, María Marqués-Torrejón
    International Journal of Molecular Sciences.2024; 25(5): 2529.     CrossRef
  • Exploring Disulfiram’s Anticancer Potential: PLGA Nano-Carriers for Prolonged Drug Delivery and Potential Improved Therapeutic Efficacy
    Ibrahim Dumbuya, Ana Maria Pereira, Ibrahim Tolaymat, Adnan Al Dalaty, Basel Arafat, Matt Webster, Barbara Pierscionek, Mouhamad Khoder, Mohammad Najlah
    Nanomaterials.2024; 14(13): 1133.     CrossRef
  • Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma
    Rafael Jiménez, Andrada Constantinescu, Muhube Yazir, Paula Alfonso-Triguero, Raquel Pequerul, Xavier Parés, Mileidys Pérez-Alea, Ana Paula Candiota, Jaume Farrés, Julia Lorenzo
    International Journal of Molecular Sciences.2024; 25(21): 11512.     CrossRef
  • Clinical, pharmacological, and formulation evaluation of disulfiram in the treatment of glioblastoma - a systematic literature review
    Beáta-Mária Benkő, Dimitrios A. Lamprou, Anna Sebestyén, Romána Zelkó, István Sebe
    Expert Opinion on Drug Delivery.2023; 20(4): 541.     CrossRef
  • Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma
    Katja Werlenius, Sara Kinhult, Tora Skeidsvoll Solheim, Henriette Magelssen, David Löfgren, Munila Mudaisi, Sofia Hylin, Jiri Bartek, Michael Strandéus, Magnus Lindskog, Havyan Bahroz Rashid, Louise Carstam, Sasha Gulati, Ole Solheim, Jiri Bartek, Øyvind
    JAMA Network Open.2023; 6(3): e234149.     CrossRef
  • Drug repositioning of disulfiram induces endometrioid epithelial ovarian cancer cell death via the both apoptosis and cuproptosis pathways
    YAPING GAN, TING LIU, WEIFENG FENG, LIANG WANG, LI LI, YINGXIA NING
    Oncology Research.2023; 31(3): 333.     CrossRef
  • Disulfiram/Copper induces antitumor activity against gastric cancer via the ROS/MAPK and NPL4 pathways
    Yao Liu, Xin Guan, Meiling Wang, Naixue Wang, Yutong Chen, Baolei Li, Zhuxuan Xu, Fangwei Fu, Cheng Du, Zhendong Zheng
    Bioengineered.2022; 13(3): 6579.     CrossRef
  • Disulfiram in glioma: Literature review of drug repurposing
    Shiyu Zhong, Shengyu Liu, Xin Shi, Xudong Zhang, Kunhang Li, Guojun Liu, Lishuai Li, Shanwei Tao, Bowen Zheng, Weichen Sheng, Ziyin Ye, Qichen Xing, Qingqing Zhai, Lijie Ren, Ying Wu, Yijun Bao
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Multimodal targeting of glioma with functionalized nanoparticles
    Hany E. Marei
    Cancer Cell International.2022;[Epub]     CrossRef
  • Formulation Comprising Arsenic Trioxide and Dimercaprol Enhances Radiosensitivity of Pancreatic Cancer Xenografts
    Renyan Tang, Jianmin Zhu, Ying Liu, Ning Wu, Jinbin Han
    Technology in Cancer Research & Treatment.2021;[Epub]     CrossRef
  • Antioxidant and Antiproliferative Activity of Finasteride against Glioblastoma Cells
    Hyeon Ji Kim, Tae-Jun Kim, Yu Gyung Kim, Chaeeun Seong, Jin-Hwa Cho, Wanil Kim, Kyung-Ha Lee, Do-Yeon Kim
    Pharmaceutics.2021; 13(9): 1410.     CrossRef
  • Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor
    Chan-Chuan Liu, Cheng-Lin Wu, Meng-Xuan Lin, Chun-I Sze, Po-Wu Gean
    International Journal of Molecular Sciences.2021; 22(19): 10496.     CrossRef
  • Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study
    Lisa Zirjacks, Nicolai Stransky, Lukas Klumpp, Lukas Prause, Franziska Eckert, Daniel Zips, Sabine Schleicher, Rupert Handgretinger, Stephan M. Huber, Katrin Ganser
    Biomolecules.2021; 11(11): 1561.     CrossRef
  • The combination of disulfiram and copper for cancer treatment
    Hong Li, Jingyu Wang, Chunfu Wu, Lihui Wang, Zhe-Sheng Chen, Wei Cui
    Drug Discovery Today.2020; 25(6): 1099.     CrossRef
  • Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme
    Jinyeong Choi, Gaeun Kim, Su Bin Cho, Hyung-Jun Im
    Journal of Nanobiotechnology.2020;[Epub]     CrossRef
  • Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma—Old Myth or New Logos?
    Francisco Meraz-Torres, Sarah Plöger, Claus Garbe, Heike Niessner, Tobias Sinnberg
    Cancers.2020; 12(12): 3538.     CrossRef
  • Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents
    Elmira Ekinci, Sagar Rohondia, Raheel Khan, Qingping P. Dou
    Recent Patents on Anti-Cancer Drug Discovery.2019; 14(2): 113.     CrossRef
  • 9,817 View
  • 298 Download
  • 20 Web of Science
  • 18 Crossref
Close layer
Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type
Hyun Jee Kim, Chan-Young Ock, Tae Min Kim, Sung Hee Lee, Ju-Yeun Lee, Sun hoi Jung, Yoon Sook Cho, Miso Kim, Bhumsuk Keam, Dong-Wan Kim, Il Han Kim, Dae Seog Heo
Cancer Res Treat. 2018;50(3):670-680.   Published online July 3, 2017
DOI: https://doi.org/10.4143/crt.2017.051
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The aim of this study was to compare asparaginase-related toxicities in two asparaginase preparations, namely native Escherichia coli L-asparaginase (L-ASP) and pegylated asparaginase (PEG-ASP) in combination with ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) in natural killer (NK)/T-cell lymphoma (NTCL).
Materials and Methods
A total of 41 NTCL patients who received IMEP plus native E. coli L-ASP or PEG-ASP at Seoul National University Hospital were included in this study between January 2013 and March 2016. IMEP/ASP treatment consisted of ifosfamide, methotrexate, etoposide, plus native E. coli L-ASP (6,000 IU/m2 on days 1, 3, 5, 7, 9, and 11) or PEG-ASP (2,500 IU/m2 on day 1) every 3 weeks. ASP-related toxicities, toxicity patterns, length of hospital stay, and clinical outcomes were compared between the different treatment groups.
Results
The frequency of ASP-related toxicities was similar between the IMEP plus native E. coli L-ASP group and the PEG-ASP group apart from hypofibrinogenemia (native E. coli L-ASP vs. PEG-ASP group, 86.4% vs. 36.8%; p=0.001). Although post-treatment transaminase and albumin levels were significantly high and low, respectively, hepatotoxicity gradients before and after treatment did not differ significantly between the groups. Since PEG-ASP was given at an outpatient clinic in some patients, length of hospital stay was significantly shorter in the IMEP plus PEG-ASP group (median, 4.0 vs. 6.0 days; p=0.002). A favorable tendency of clinical outcomes was observed in NTCL patients treated with IMEP plus PEG-ASP (complete remission rate, 73.7% vs. 45.5%; p=0.067).
Conclusion
IMEP plus PEG-ASP showed similar ASP-related toxicities, shorter length of hospital stay, and a trend towards improved clinical outcomes compared with IMEP plus native E. coli L-ASP in NTCL.

Citations

Citations to this article as recorded by  
  • Pharmacovigilance analysis of drug-induced hypofibrinogenemia using the FDA Adverse Event Reporting System
    Xiao Wen, Le Cai, Ao Gao, An Fu, Daihong Guo, Man Zhu
    International Journal of Clinical Pharmacy.2025;[Epub]     CrossRef
  • New Facets of Hematolymphoid Eponymic Diseases
    Chi Sing Ng, Jilong Qin
    Lymphatics.2025; 3(2): 9.     CrossRef
  • From the midfacial destructive drama to the unfolding EBV story: a short history of EBV-positive NK-cell and T-cell lymphoproliferative diseases
    Chi Sing Ng
    Pathology.2024; 56(6): 773.     CrossRef
  • Treatment of extranodal NK/T-cell lymphoma: From past to future
    Zheng Yan, Shuna Yao, Zhizhong Wang, Wenping Zhou, Zhihua Yao, Yanyan Liu
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L‐asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T‐cell lymphoma: A French retrospective study
    Sammara Chaubard, Amira Marouf, David Lavergne, François Lemonnier, Julien Rossignol, Aline Clavert, Rémy Gressin, Guillaume Cartron, Agathe Waultier‐Rascalou, Jacques Vargaftig, Gilles Salles, Emmanuel Bachy, Hervé Ghesquières, Olivier Tournilhac, Adrien
    British Journal of Haematology.2023; 201(4): 673.     CrossRef
  • Is PEGylation of Drugs Associated with Hypersensitivity Reactions? An Analysis of the Italian National Spontaneous Adverse Drug Reaction Reporting System
    Salvatore Crisafulli, Paola Maria Cutroneo, Nicoletta Luxi, Andrea Fontana, Carmen Ferrajolo, Pasquale Marchione, Laura Sottosanti, Giovanna Zanoni, Ugo Moretti, Silvia Franzè, Paola Minghetti, Gianluca Trifirò
    Drug Safety.2023; 46(4): 343.     CrossRef
  • Incidence and Related Factors of L-asparaginase-induced Hypersensitivity Reactions Requiring Treatment Changes in Pediatric Patients with Acute Lymphoblastic Leukemia
    Eun Eui Noh, Yujin Lee, Sukmin Hong, Sung Hwan Kim, Sung Yun Suh, Yoon Sook Cho, Hyun Jin Park, Bo Kyung Kim, Kyung Taek Hong, Jung Yoon Choi, Hyoung Jin Kang, Ju-Yeun Lee
    Journal of Korean Society of Health-System Pharmacists.2023; 40(2): 171.     CrossRef
  • DDGP followed by radiotherapy vs VIPD followed by radiotherapy in newly diagnosed early NK/T-cell lymphoma
    Lei Zhang, Chenxing Shangguan, Xin Li, Ling Li, Xinhua Wang, Xiaorui Fu, Zhenchang Sun, Yonggang Shi, Jingjing Wu, Xudong Zhang, Hui Yu, Feifei Nan, Jiaqin Yan, Yu Chang, Zhiyuan Zhou, Xiaolong Wu, Xiaoyan Feng, Xiyang Liu, Hongwei Xue, Liqun Zou, Yi Lu,
    Leukemia Research.2022; 118: 106881.     CrossRef
  • DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients
    Xin Wang, Junxia Hu, Meng Dong, Mengjie Ding, Linan Zhu, Jingjing Wu, Zhenchang Sun, Xin Li, Lei Zhang, Ling Li, Xinhua Wang, Xiaorui Fu, Guannan Wang, Qingjiang Chen, Mingzhi Zhang, Xudong Zhang
    Clinical and Translational Science.2021; 14(1): 405.     CrossRef
  • Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge
    Yiwei Liu, Colton A. Smith, John C. Panetta, Wenjian Yang, Lauren E. Thompson, Jacob P. Counts, Alejandro R. Molinelli, Deqing Pei, Nancy M. Kornegay, Kristine R. Crews, Hope Swanson, Cheng Cheng, Seth E. Karol, William E. Evans, Hiroto Inaba, Ching-Hon P
    Journal of Clinical Oncology.2019; 37(23): 2051.     CrossRef
  • Multiple drugs

    Reactions Weekly.2018; 1717(1): 197.     CrossRef
  • PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity
    Wen Zheng, Yuhuan Gao, Xiaoyan Ke, Weijing Zhang, Liping Su, Hanyun Ren, Ningjing Lin, Yan Xie, Meifeng Tu, Weiping Liu, Lingyan Ping, Zhitao Ying, Chen Zhang, Lijuan Deng, Xiaopei Wang, Yuqin Song, Jun Zhu
    BMC Cancer.2018;[Epub]     CrossRef
  • 12,534 View
  • 393 Download
  • 9 Web of Science
  • 12 Crossref
Close layer
Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma
Young-Bem Se, Seung Hyun Kim, Ji Young Kim, Ja Eun Kim, Yun-Sik Dho, Jin Wook Kim, Yong Hwy Kim, Hyun Goo Woo, Se-Hyuk Kim, Shin-Hyuk Kang, Hak Jae Kim, Tae Min Kim, Soon-Tae Lee, Seung Hong Choi, Sung-Hye Park, Il Han Kim, Dong Gyu Kim, Chul-Kee Park
Cancer Res Treat. 2017;49(2):387-398.   Published online July 19, 2016
DOI: https://doi.org/10.4143/crt.2016.106
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Homeobox (HOX) genes are essential developmental regulators that should normally be in the silenced state in an adult brain. The aberrant expression of HOX genes has been associated with the prognosis of many cancer types, including glioblastoma (GBM). This study examined the identity and role of HOX genes affecting GBM prognosis and treatment resistance.
Materials and Methods
The full series of HOX genes of five pairs of initial and recurrent human GBM samples were screened by microarray analysis to determine the most plausible candidate responsible for GBM prognosis. Another 20 newly diagnosed GBM samples were used for prognostic validation. In vitro experiments were performed to confirm the role of HOX in treatment resistance. Mediators involved in HOX gene regulation were searched using differentially expressed gene analysis, gene set enrichment tests, and network analysis.
Results
The underexpression of HOXA11 was identified as a consistent signature for a poor prognosis among the HOX genes. The overall survival of the GBM patients indicated a significantly favorable prognosis in patients with high HOXA11 expression (31±15.3 months) compared to the prognoses in thosewith lowHOXA11 expression (18±7.3 months, p=0.03). When HOXA11 was suppressed in the GBM cell lines, the anticancer effect of radiotherapy and/or temozolomide declined. In addition, five candidate mediators (TGFBR2, CRIM1, TXNIP, DPYSL2, and CRMP1) that may confer an oncologic effect after HOXA11 suppression were identified.
Conclusion
The treatment resistance induced by the underexpression of HOXA11 can contribute to a poor prognosis in GBM. Further investigation will be needed to confirm the value of HOXA11 as a potential target for overcoming the treatment resistance by developing chemo- or radiosensitizers.

Citations

Citations to this article as recorded by  
  • HOX gene dysregulation in glioblastoma: a narrative review of current advances
    Suleyman Hekim, Severa Bunda, Shaliman Dilibaerguli, Maierdan Palihati, Yasin Mamatjan
    Discover Oncology.2025;[Epub]     CrossRef
  • Intratumoral IL-12 delivery via mesenchymal stem cells combined with PD-1 blockade leads to long-term antitumor immunity in a mouse glioblastoma model
    Junseong Park, Soon A. Park, Yoon-Seob Kim, Dokyeong Kim, Sun Shin, Sug Hyung Lee, Sin-Soo Jeun, Yeun-Jun Chung, Stephen Ahn
    Biomedicine & Pharmacotherapy.2024; 173: 115790.     CrossRef
  • Dihydropyrimidinase‐like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia
    Fenglin Li, Qing Ling, Jiaying Lian, Ying Chen, Chao Hu, Min Yang, Xiang Zhang, Chenying Li, Shihui Mao, Wenle Ye, Xia Li, Xiangjie Lin, Wenwen Wei, Xin Huang, Jiajia Pan, Yu Qian, Jinghan Wang, Ying Lu, Jie Jin
    Cancer Medicine.2023; 12(7): 8319.     CrossRef
  • Development and validation of a predictive model in diagnosis and prognosis of primary glioblastoma patients based on Homeobox A family
    Zong-Qing Zheng, Gui-Qiang Yuan, Guo-Guo Zhang, Qian-Qian Nie, Zhong Wang
    Discover Oncology.2023;[Epub]     CrossRef
  • HOXA11-AS aggravates microglia-induced neuroinflammation after traumatic brain injury
    Xiang-Long Li, Bin Wang, Fu-Bing Yang, Li-Gang Chen, Jian You
    Neural Regeneration Research.2022; 17(5): 1096.     CrossRef
  • Molecular implications of HOX genes targeting multiple signaling pathways in cancer
    U Sangeetha Shenoy, Divya Adiga, Shama Prasada Kabekkodu, Keith D Hunter, Raghu Radhakrishnan
    Cell Biology and Toxicology.2022; 38(1): 1.     CrossRef
  • High expression ofHOXA4in patients with glioma indicates unfavorable clinical outcomes
    Zhenghong Yu, Zhendong Liu, Xiaoyu Lian, Xingbo Cheng, Binfeng Liu, Bo Zhang, Hongbo Wang, Jialin Wang, Ang Li, Zhishuai Ren, Bo Pang, Rongjun Qian, Yanzheng Gao
    Cell Cycle.2022; 21(22): 2387.     CrossRef
  • Downregulation of HOXA11 enhances endometrial cancer malignancy and cisplatin resistance via activating PTEN/AKT signaling pathway
    C. Kong, Z. Zhu, Y. Li, P. Xue, L. Chen
    Clinical and Translational Oncology.2021; 23(7): 1334.     CrossRef
  • Long Non-Coding RNAs in Diagnosis, Treatment, Prognosis, and Progression of Glioma: A State-of-the-Art Review
    Sara Momtazmanesh, Nima Rezaei
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
    Srikumar Chakravarthi, Barani Karikalan
    Current Cancer Therapy Reviews.2021; 17(2): 97.     CrossRef
  • HOX gene cluster (de)regulation in brain: from neurodevelopment to malignant glial tumours
    Céline S. Gonçalves, Elisa Le Boiteux, Philippe Arnaud, Bruno M. Costa
    Cellular and Molecular Life Sciences.2020; 77(19): 3797.     CrossRef
  • Expression Profile and Prognostic Values of HOXA Family Members in Laryngeal Squamous Cell Cancer
    Jinyun Li, Meng Ye, Chongchang Zhou
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Methylation in HOX Clusters and Its Applications in Cancer Therapy
    Ana Paço, Simone Aparecida de Bessa Garcia, Renata Freitas
    Cells.2020; 9(7): 1613.     CrossRef
  • N6-Methylandenosine-Related lncRNAs Are Potential Biomarkers for Predicting the Overall Survival of Lower-Grade Glioma Patients
    Zewei Tu, Lei Wu, Peng Wang, Qing Hu, Chuming Tao, Kuangxun Li, Kai Huang, Xingen Zhu
    Frontiers in Cell and Developmental Biology.2020;[Epub]     CrossRef
  • Targeting HOX/PBX dimer formation as a potential therapeutic option in esophageal squamous cell carcinoma
    Lu‐Yan Shen, Ting Zhou, Ya‐Bing Du, Qi Shi, Ke‐Neng Chen
    Cancer Science.2019; 110(5): 1735.     CrossRef
  • An inverse interaction betweenHOXA11andHOXA11-ASis associated with cisplatin resistance in lung adenocarcinoma
    Youwei Zhang, Yuan Yuan, Yang Li, Peiying Zhang, Pingsheng Chen, Sanyuan Sun
    Epigenetics.2019; 14(10): 949.     CrossRef
  • Long noncoding RNA HOXA11-AS promotes gastric cancer cell proliferation and invasion via SRSF1 and functions as a biomarker in gastric cancer
    Yun Liu, Yu-Mei Zhang, Feng-Bo Ma, Su-Rong Pan, Bao-Zhen Liu
    World Journal of Gastroenterology.2019; 25(22): 2763.     CrossRef
  • DNA methylation changes following DNA damage in prostate cancer cells
    Laura P. Sutton, Sarah A. Jeffreys, Jessica L. Phillips, Phillippa C. Taberlay, Adele F. Holloway, Mark Ambrose, Ji-Hoon E. Joo, Arabella Young, Rachael Berry, Marketa Skala, Kate H. Brettingham-Moore
    Epigenetics.2019; 14(10): 989.     CrossRef
  • MicroRNA‐128/homeobox B8 axis regulates ovarian cancer cell progression
    Rui Li, Lingling Gong, Pin Li, Jing Wang, Liangliang Bi
    Basic & Clinical Pharmacology & Toxicology.2019; 125(6): 499.     CrossRef
  • Evaluation of the HOXA11 level in patients with lung squamous cancer and insights into potential molecular pathways via bioinformatics analysis
    Rui Zhang, Tong-tong Zhang, Gao-qiang Zhai, Xian-yu Guo, Yuan Qin, Ting-qing Gan, Yu Zhang, Gang Chen, Wei-jia Mo, Zhen-bo Feng
    World Journal of Surgical Oncology.2018;[Epub]     CrossRef
  • HOXA11 antisense long noncoding RNA (HOXA11‐AS): A promising lncRNA in human cancers
    Cheng‐Wei Lu, Dan‐Dan Zhou, Tian Xie, Ji‐Long Hao, Om Prakash Pant, Cheng‐Bo Lu, Xiu‐Fen Liu
    Cancer Medicine.2018; 7(8): 3792.     CrossRef
  • Identification of radiation responsive genes and transcriptome profiling via complete RNA sequencing in a stable radioresistant U87 glioblastoma model
    Ninh B. Doan, Ha S. Nguyen, Hisham S. Alhajala, Basem Jaber, Mona M. Al-Gizawiy, Eun-Young Erin Ahn, Wade M. Mueller, Christopher R. Chitambar, Shama P. Mirza, Kathleen M. Schmainda
    Oncotarget.2018; 9(34): 23532.     CrossRef
  • Upregulation of HOXA11 during the progression of lung adenocarcinoma detected via multiple approaches
    Xia Yang, Yun Deng, Rong‑Quan He, Xiao‑Jiao Li, Jie Ma, Gang Chen, Xiao‑Hua Hu
    International Journal of Molecular Medicine.2018;[Epub]     CrossRef
  • Clinical Significance and Effect of lncRNA HOXA11-AS in NSCLC: A Study Based on Bioinformatics, In Vitro and in Vivo Verification
    Yu Zhang, Wen-jie Chen, Ting-qing Gan, Xiu-ling Zhang, Zu-cheng Xie, Zhi-hua Ye, Yun Deng, Ze-feng Wang, Kai-teng Cai, Shi-kang Li, Dian-zhong Luo, Gang Chen
    Scientific Reports.2017;[Epub]     CrossRef
  • Functional analysis of HOXA10 and HOXB4 in human medulloblastoma cell lines
    Ricardo Bonfim-Silva, Fernanda Ursoli Ferreira Melo, Carolina Hassibe Thomé, Kuruvilla Joseph Abraham, Fábio Augusto Labre De Souza, Fernando Silva Ramalho, Hélio Rubens Machado, Ricardo Santos De Oliveira, Angelo A. Cardoso, Dimas Tadeu Covas, Aparecida
    International Journal of Oncology.2017; 51(6): 1929.     CrossRef
  • Long non-coding RNA HOXA11-AS promotes cell proliferation and metastasis in human breast cancer
    Jian-Chun Su, Xue-Feng Hu
    Molecular Medicine Reports.2017; 16(4): 4887.     CrossRef
  • Identification of skin-related lncRNAs as potential biomarkers that are involved in Wnt pathways in keloids
    Xiao-Jie Sun, Qiang Wang, Baofeng Guo, Xian-Ying Liu, Bing Wang
    Oncotarget.2017; 8(21): 34236.     CrossRef
  • Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia
    Hongmei Luo, Yu Qin, Frederic Reu, Sujuan Ye, Yang Dai, Jingcao Huang, Fangfang Wang, Dan Zhang, Ling Pan, Huanling Zhu, Yu Wu, Ting Niu, Zhijian Xiao, Yuhuan Zheng, Ting Liu
    Journal of Hematology & Oncology.2016;[Epub]     CrossRef
  • 15,439 View
  • 330 Download
  • 31 Web of Science
  • 28 Crossref
Close layer
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
Byung Sup Kim, Ho Jun Seol, Do-Hyun Nam, Chul-Kee Park, Il Han Kim, Tae Min Kim, Jeong Hoon Kim, Young Hyun Cho, Sang Min Yoon, Jong Hee Chang, Seok-Gu Kang, Eui Hyun Kim, Chang-Ok Suh, Tae-Young Jung, Kyung-Hwa Lee, Chae-Yong Kim, In Ah Kim, Chang-Ki Hong, Heon Yoo, Jin Hee Kim, Shin-Hyuk Kang, Min Kyu Kang, Eun-Young Kim, Sun-Hwan Kim, Dong-Sup Chung, Sun-Chul Hwang, Joon-Ho Song, Sung Jin Cho, Sun-Il Lee, Youn-Soo Lee, Kook-Jin Ahn, Se Hoon Kim, Do Hun Lim, Ho-Shin Gwak, Se-Hoon Lee, Yong-Kil Hong
Cancer Res Treat. 2017;49(1):193-203.   Published online June 27, 2016
DOI: https://doi.org/10.4143/crt.2015.473
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to investigate the feasibility and survival benefits of combined treatment with radiotherapy and adjuvant temozolomide (TMZ) in a Korean sample.
Materials and Methods
A total of 750 Korean patients with histologically confirmed glioblastoma multiforme, who received concurrent chemoradiotherapy with TMZ (CCRT) and adjuvant TMZ from January 2006 until June 2011, were analyzed retrospectively.
Results
After the first operation, a gross total resection (GTR), subtotal resection (STR), partial resection (PR), biopsy alone were achieved in 388 (51.7%), 159 (21.2%), 96 (12.8%), and 107 (14.3%) patients,respectively. The methylation status of O6-methylguanine-DNA methyltransferase (MGMT) was reviewed retrospectively in 217 patients. The median follow-up period was 16.3 months and the median overall survival (OS) was 17.5 months. The actuarial survival rates at the 1-, 3-, and 5-year OS were 72.1%, 21.0%, and 9.0%, respectively. The median progression-free survival (PFS) was 10.1 months, and the actuarial PFS at 1-, 3-, and 5-year PFS were 42.2%, 13.0%, and 7.8%, respectively. The patients who received GTR showed a significantly longer OS and PFS than those who received STR, PR, or biopsy alone, regardless of the methylation status of the MGMT promoter. Patients with a methylated MGMT promoter also showed a significantly longer OS and PFS than those with an unmethylated MGMT promoter. Patients who received more than six cycles of adjuvant TMZ had a longer OS and PFS than those who received six or fewer cycles. Hematologic toxicity of grade 3 or 4 was observed in 8.4% of patients during the CCRT period and in 10.2% during the adjuvant TMZ period.
Conclusion
Patients treated with CCRT followed by adjuvant TMZ had more favorable survival rates and tolerable toxicity than those who did not undergo this treatment.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection
    Masayuki Kanamori, Ichiyo Shibahara, Yoshiteru Shimoda, Yukinori Akiyama, Takaaki Beppu, Shigeo Ohba, Toshiyuki Enomoto, Takahiro Ono, Yuta Mitobe, Mitsuto Hanihara, Yohei Mineharu, Joji Ishida, Kenichiro Asano, Yasuyuki Yoshida, Manabu Natsumeda, Sadahir
    International Journal of Clinical Oncology.2025; 30(1): 51.     CrossRef
  • Iron Mediates Radiation-Induced Glioblastoma Cell Diffusion
    Stephenson Boakye Owusu, Akalanka B. Ekanayake, Alexei V. Tivanski, Michael S. Petronek
    International Journal of Molecular Sciences.2025; 26(10): 4755.     CrossRef
  • Letter to the Editor Regarding Cerebral Blood Flow Role in Delineating Treatment Effect from True Tumor Progression in Glioblastoma Multiforme
    Inibehe Ime Okon, Tolulope Judah Gbayisomore, Samuel Berchi Kankam, Mohammad Jalloh
    World Neurosurgery.2024; 186: 269.     CrossRef
  • NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors
    Eric Eunshik Kim, Chul-Kee Park, Seung-Ki Kim, Ji Hoon Phi, Sun Ha Paek, Jung Yoon Choi, Hyoung Jin Kang, Joo Ho Lee, Jae Kyung Won, Hongseok Yun, Sung-Hye Park
    Acta Neuropathologica Communications.2024;[Epub]     CrossRef
  • The Korean Society for Neuro-Oncology (KSNO) Guideline for the Management of Brain Tumor Patients During the Crisis Period: A Consensus Recommendation Using the Delphi Method (Version 2023.1)
    Min-Sung Kim, Se-Il Go, Chan Woo Wee, Min Ho Lee, Seok-Gu Kang, Kyeong-O Go, Sae Min Kwon, Woohyun Kim, Yun-Sik Dho, Sung-Hye Park, Youngbeom Seo, Sang Woo Song, Stephen Ahn, Hyuk-Jin Oh, Hong In Yoon, Sea-Won Lee, Joo Ho Lee, Kyung Rae Cho, Jung Won Choi
    Brain Tumor Research and Treatment.2023; 11(2): 123.     CrossRef
  • Lymphoproliferative disorder during temozolomide therapy; a representative case of a formidable complication and management challenges
    Daisuke Sato, Hirokazu Takami, Shunsaku Takayanagi, Kazuki Taoka, Mariko Tanaka, Reiko Matsuura, Shota Tanaka, Nobuhito Saito
    BMC Neurology.2023;[Epub]     CrossRef
  • Glioma angiogenesis is boosted by ELK3 activating the HIF-1$$alpha$$/VEGF-A signaling axis
    Mou Yueyang, Hu Yaqin, Xue Guolian, Zhao Wenjian, Jiao Yang, Li Chen, Cao Haiyan, Chao Min, Deng Jianping, Dai Penggao, Zhu Hongli, Wang Liang
    BMC Cancer.2023;[Epub]     CrossRef
  • Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open‐label phase 2 study
    Kihwan Hwang, Junhyung Kim, Seok‐Gu Kang, Tae‐Young Jung, Jeong Hoon Kim, Se‐Hyuk Kim, Shin‐Hyuk Kang, Yong‐Kil Hong, Tae Min Kim, Yu Jung Kim, Byung Se Choi, Jong Hee Chang, Chae‐Yong Kim
    Cancer Medicine.2022; 11(2): 371.     CrossRef
  • Prognostic Value and Risk Factors of Treatment-Related Lymphopenia in Malignant Glioma Patients Treated With Chemoradiotherapy: A Systematic Review and Meta-Analysis
    Yongchao Zhang, Shichao Chen, Hualei Chen, Shanshan Chen, Zhen Li, Enshan Feng, Wei Li
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • PrACTiC: A Predictive Algorithm for Chemoradiotherapy-Induced Cytopenia in Glioblastoma Patients
    Alireza Amouheidari, Zahra Alirezaei, Stefan Rauh, Masoud Hassanpour, Ozkan Kanat
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Relapsing High—Grade Glioma from Peritumoral Zone: Critical Review of Radiotherapy Treatment Options
    Maria Chiara Lo Greco, Roberto Milazzotto, Rocco Luca Emanuele Liardo, Grazia Acquaviva, Madalina La Rocca, Roberto Altieri, Francesco Certo, Giuseppe Maria Barbagallo, Antonio Basile, Pietro Valerio Foti, Stefano Palmucci, Stefano Pergolizzi, Antonio Pon
    Brain Sciences.2022; 12(4): 416.     CrossRef
  • Effect of Choline Alphoscerate on the Survival of Glioblastoma Patients: A Retrospective, Single-Center Study
    Yeong Jin Kim, Tae-Kyu Lee, Myung-Giun Noh, Tae-Young Jung, In-Young Kim, Shin Jung, Kyung-Hwa Lee, Kyung-Sub Moon
    Journal of Clinical Medicine.2022; 11(20): 6052.     CrossRef
  • Evaluating survival in subjects with astrocytic brain tumors by dynamic susceptibility-weighted perfusion MR imaging
    Matthew L. White, Yan Zhang, Syed A. Jaffar Kazmi, Michele Aizenberg, Nicole Shonka, Fang Yu, Adams Kusi Appiah, Michael C. Burger
    PLOS ONE.2021; 16(1): e0244275.     CrossRef
  • Prognostic value of test(s) for O6-methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide
    Alexandra McAleenan, Claire Kelly, Francesca Spiga, Ashleigh Kernohan, Hung-Yuan Cheng, Sarah Dawson, Lena Schmidt, Tomos Robinson, Sebastian Brandner, Claire L Faulkner, Christopher Wragg, Sarah Jefferies, Amy Howell, Luke Vale, Julian P T Higgins, Kathr
    Cochrane Database of Systematic Reviews.2021;[Epub]     CrossRef
  • Mixed malignant glioblastoma and schwannoma in spinal cord with metachronous ependymoma: A case report
    Mostafa Farzin, Mohamadreza Hajiabadi, Mohammad Rahmani, Kasra Kolahdouzan
    Clinical Case Reports.2021;[Epub]     CrossRef
  • Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study
    Srinivas Annavarapu, Anagha Gogate, Trang Pham, Kalatu Davies, Prianka Singh, Nicholas Robert
    CNS Oncology.2021;[Epub]     CrossRef
  • A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma
    Fahimeh Attarian, Farzad Taghizadeh-Hesary, Azar Fanipakdel, Seyed Alireza Javadinia, Pejman Porouhan, Babak PeyroShabany, Danial Fazilat-Panah
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial
    Chae-Yong Kim, Sun Ha Paek, Do-hyun Nam, Jong-Hee Chang, Yong-Kil Hong, Jeong Hoon Kim, Oh Lyong Kim, Se-Hyuk Kim
    Journal of Neuro-Oncology.2020; 146(3): 399.     CrossRef
  • Risk Factors for Cognitive Impairment in High-Grade Glioma Patients Treated with Postoperative Radiochemotherapy
    Qiang Wang, Fengxia Xiao, Fei Qi, Xiaopeng Song, Yonghua Yu
    Cancer Research and Treatment.2020; 52(2): 586.     CrossRef
  • Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
    Maria B. Garcia-Fabiani, Maria Ventosa, Andrea Comba, Marianela Candolfi, Alejandro J. Nicola Candia, Mahmoud S. Alghamri, Padma Kadiyala, Stephen Carney, Syed M. Faisal, Anna Schwendeman, James J. Moon, Lindsay Scheetz, Joerg Lahann, Ava Mauser, Pedro R.
    Expert Opinion on Investigational Drugs.2020; 29(7): 659.     CrossRef

  • Long Intergenic Non-Protein Coding RNA 1094 Promotes Initiation and Progression of Glioblastoma by Promoting microRNA-577-Regulated Stabilization of Brain-Derived Neurotrophic Factor


    Xiaoyan Dong, Xiuxin Fu, Miao Yu, Zengfen Li
    Cancer Management and Research.2020; Volume 12: 5619.     CrossRef
  • SNHG7 Facilitates Glioblastoma Progression by Functioning as a Molecular Sponge for MicroRNA-449b-5p and Thereby Increasing MYCN Expression
    Yaogang Chen, Shaoyong Yuan, Tieying Ning, Huiqing Xu, Bo Guan
    Technology in Cancer Research & Treatment.2020;[Epub]     CrossRef
  • Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres
    Hyeong-Cheol Oh, Jin-Kyoung Shim, Junseong Park, Ji-Hyun Lee, Ran Joo Choi, Nam Hee Kim, Hyun Sil Kim, Ju Hyung Moon, Eui Hyun Kim, Jong Hee Chang, Jong In Yook, Seok-Gu Kang
    Journal of Cancer Research and Clinical Oncology.2020; 146(11): 2817.     CrossRef
  • Clinical Characteristics of High-Grade Glioma with Primary Leptomeningeal Seeding at Initial Diagnosis in a Single Center Study
    Ji-Eyon Kwon, Kihwan Hwang, Kyeong-O Go, Chan Woo Wee, In Ah Kim, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Jung Ho Han, Chae-Yong Kim
    Brain Tumor Research and Treatment.2020; 8(2): 77.     CrossRef
  • A Longitudinal Study of Lipid Peroxidation and Symptom Clusters in Patients With Brain Cancers
    Sanghee Kim
    Nursing Research.2018; 67(5): 387.     CrossRef
  • Dynamic Susceptibility Contrast (DSC) Perfusion MR in the Prediction of Long-Term Survival of Glioblastomas (GBM): Correlation with MGMT Promoter Methylation and 1p/19q Deletions
    Yong Wonn Kwon, Won-Jin Moon, Mina Park, Hong Gee Roh, Young Cho Koh, Sang Woo Song, Jin Woo Choi
    Investigative Magnetic Resonance Imaging.2018; 22(3): 158.     CrossRef
  • Notch1ablation radiosensitizes glioblastoma cells
    Na Han, Guangyuan Hu, Lei Shi, Guoxian Long, Lin Yang, Qingsong Xi, Qiuyun Guo, Jianhua Wang, Zhen Dong, Mengxian Zhang
    Oncotarget.2017; 8(50): 88059.     CrossRef
  • Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system
    Haihui Jiang, Yong Cui, Junmei Wang, Song Lin
    Oncotarget.2017; 8(12): 20354.     CrossRef
  • 16,416 View
  • 314 Download
  • 25 Web of Science
  • 28 Crossref
Close layer
Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma
Yongjun Cha, Yu Jung Kim, Se-Hoon Lee, Tae-Min Kim, Seung Hong Choi, Dong-Wan Kim, Chul-Kee Park, Il Han Kim, Jee Hyun Kim, Eunhee Kim, Byungse Choi, Chae-Yong Kim, In Ah Kim, Dae Seog Heo
Cancer Res Treat. 2017;49(1):129-140.   Published online May 18, 2016
DOI: https://doi.org/10.4143/crt.2015.466
AbstractAbstract PDFPubReaderePub
Purpose
Bevacizumab±irinotecan is effective for treatment of recurrent malignant gliomas. However, the optimal duration of treatment has not been established.
Materials and Methods
Ninety-four consecutive patients with recurrent malignant glioma who were treated with bevacizumab at our institutions were identified. Patients who continued bevacizumab until tumor progression were enrolled in a late discontinuation (LD) group, while those who stopped bevacizumab before tumor progression were enrolled in an early discontinuation (ED) group. Landmark analyses were performed at weeks 9, 18, and 26 for comparison of patient survival between the two groups.
Results
Among 89 assessable patients, 62 (69.7%) and 27 (30.3%) patients were categorized as the LD and ED groups, respectively. According to landmark analysis, survival times from weeks 9, 18, and 26 were not significantly different between the two groups in the overall population. However, the LD group showed a trend toward increased survival compared to the ED group among responders. In the ED group, the median time from discontinuation to disease progression was 11.4 weeks, and none of the patients showed a definite rebound phenomenon. Similar median survival times after disease progression were observed between groups (14.4 weeks vs. 15.7 weeks, p=0.251). Of 83 patients, 38 (45.8%) received further therapy at progression, and those who received further therapy showed longer survival in both the LD and ED groups.
Conclusion
In recurrent malignant glioma, duration of bevacizumab was not associated with survival time in the overall population. However, ED of bevacizumab in responding patients might be associated with decreased survival.

Citations

Citations to this article as recorded by  
  • The Vascular Microenvironment in Glioblastoma: A Comprehensive Review
    Alejandra Mosteiro, Leire Pedrosa, Abel Ferrés, Diouldé Diao, Àngels Sierra, José Juan González
    Biomedicines.2022; 10(6): 1285.     CrossRef
  • Differential P-Glycoprotein/CD31 Expression as Markers of Vascular Co-Option in Primary Central Nervous System Tumors
    Tiziana Annese, Mariella Errede, Antonio d’Amati, Michelina De Giorgis, Loredana Lorusso, Roberto Tamma, Domenico Ribatti
    Diagnostics.2022; 12(12): 3120.     CrossRef
  • Identification of diverse tumor endothelial cell populations in malignant glioma
    Jeff C Carlson, Manuel Cantu Gutierrez, Brittney Lozzi, Emmet Huang-Hobbs, Williamson D Turner, Burak Tepe, Yiqun Zhang, Alexander M Herman, Ganesh Rao, Chad J Creighton, Joshua D Wythe, Benjamin Deneen
    Neuro-Oncology.2021; 23(6): 932.     CrossRef
  • Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy
    Charlotte Bronnimann, Cristina Izquierdo, Stéphanie Cartalat, Laure Thomas, Bastien Joubert, Laura Delpech, Marc Barritault, David Meyronet, Jérôme Honnorat, François Ducray
    Journal of Neuro-Oncology.2018; 138(1): 141.     CrossRef
  • 10,715 View
  • 182 Download
  • 5 Web of Science
  • 4 Crossref
Close layer
Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization
Jin Ho Kim, Sung Ho Moon, Mina No, Jae Jin Kim, Eun Jung Choi, Bong Jun Cho, Jae Sung Kim, Il Han Kim, In Ah Kim
Cancer Res Treat. 2016;48(3):1130-1140.   Published online November 17, 2015
DOI: https://doi.org/10.4143/crt.2015.206
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Histone deacetylase (HDAC) inhibitors radiosensitize tumor cells. To elucidate mechanisms underlying radiosensitization by HDAC inhibition, understanding of differential contributions of HDAC isotypes is needed. The aim of this study was to investigate involvement of known HDAC isotypes in modulation of cellular radiosensitivity. Materials and Methods Because pharmacologic HDAC inhibitors lack isotype-specificity, RNA interference against 11 HDAC isotypes was used to inhibit HDAC in an isotype-specific manner. Radiation cell survival was evaluated using a clonogenic assay in SQ20B cells transfected with small interfering RNA specifically targeting HDAC isotypes. Immunocytochemistry was performed for detection of γH2AX foci. Protein expression was measured using Western blotting.
Results
Among 11 HDAC isotypes tested, specific inhibition of 7 isotypes (HDAC1, HDAC3, HDAC4, HDAC6, HDAC7, HDAC10, and HDAC11) enhanced radiation lethality in SQ20B cells. Radiosensitization by inhibition of these HDAC isotypes was accompanied by delay of DNA double strand break repair. Radiosensitivity of SQ20B cells was not altered by selective inhibition of the remaining four isotypes (HDAC2, HDAC5, HDAC8, and HDAC9). Inhibition of HDAC isotypes resulted in downregulation of various proteins involved in pro-survival and DNA damage repair pathways. Conclusion Isotype-specificity exists in HDAC inhibition-induced radiosensitization. Different HDAC isotypes are differentially involved in modulation of cellular radiosensitivity.

Citations

Citations to this article as recorded by  
  • Histone Deacetylase 6 (HDAC6) in Ciliopathies: Emerging Insights and Therapeutic Implications
    Zhiyi Wang, Xiaofan Zhu, Zhenzhou Huang, Kaidi Ren, Jie Ran, Yang Yang
    Advanced Science.2025;[Epub]     CrossRef
  • Effects of a novel HDAC6-selective inhibitor’s radiosensitization on cancer cells
    Huixiao Hu, Qi Wang, Yuni Zhang, Shuhua Yang, Aihua Shen, Junfang Yan, Denggao Zhao, Burong Hu
    Molecular Biology Reports.2024;[Epub]     CrossRef
  • HDAC11: A novel target for improved cancer therapy
    Yan Liu, Xuechao Tong, Weina Hu, Da Chen
    Biomedicine & Pharmacotherapy.2023; 166: 115418.     CrossRef
  • Histone deacetylase 10, a potential epigenetic target for therapy
    Fajuan Cheng, Bin Zheng, Jianwei Wang, Guiting Zhao, Zhongshun Yao, Zhihong Niu, Wei He
    Bioscience Reports.2021;[Epub]     CrossRef
  • Synergistic Tumoricidal Effects of Alpha-Lipoic Acid and Radiotherapy on Human Breast Cancer Cells via HMGB1
    Hoon Sik Choi, Jin Hyun Kim, Si Jung Jang, Jeong Won Yun, Ki Mun Kang, Hojin Jeong, In Bong Ha, Bae Kwon Jeong
    Cancer Research and Treatment.2021; 53(3): 685.     CrossRef
  • HDAC11: a rising star in epigenetics
    Shan-Shan Liu, Fei Wu, Yue-Mei Jin, Wei- Qin Chang, Tian-Min Xu
    Biomedicine & Pharmacotherapy.2020; 131: 110607.     CrossRef
  • Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro
    Hyeon Kang Koh, Soo Yeon Seo, Jin Ho Kim, Hak Jae Kim, Eui Kyu Chie, Seung-Ki Kim, Il Han Kim
    Cancer Research and Treatment.2019; 51(2): 696.     CrossRef
  • Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [18F]TFAHA
    Maxwell T. Laws, Robin E. Bonomi, Swatabdi Kamal, David J. Gelovani, Jeremy Llaniguez, Shreya Potukutchi, Xin Lu, Thomas Mangner, Juri G. Gelovani
    Scientific Reports.2019;[Epub]     CrossRef
  • Mechanism of the Antitumor and Radiosensitizing Effects of a Manganese Porphyrin, MnHex-2-PyP
    Sung-Won Shin, Changhoon Choi, Ga-Haeng Lee, Arang Son, Su-Hyeon Kim, Hee Chul Park, Ines Batinic-Haberle, Won Park
    Antioxidants & Redox Signaling.2017; 27(14): 1067.     CrossRef
  • MicroRNA-200c increases radiosensitivity of human cancer cells with activated EGFR-associated signaling
    Taeryool Koo, Bong Jun Cho, Dan Hyo Kim, Ji Min Park, Eun Jung Choi, Hans H. Kim, David J Lee, In Ah Kim
    Oncotarget.2017; 8(39): 65457.     CrossRef
  • Targeting Histone Deacetylase 8 as a Therapeutic Approach to Cancer and Neurodegenerative Diseases
    Alokta Chakrabarti, Jelena Melesina, Fiona R Kolbinger, Ina Oehme, Johanna Senger, Olaf Witt, Wolfgang Sippl, Manfred Jung
    Future Medicinal Chemistry.2016; 8(13): 1609.     CrossRef
  • 12,802 View
  • 154 Download
  • 11 Web of Science
  • 11 Crossref
Close layer
Radiation-Induced Sarcoma: A 15-Year Experience in a Single Large Tertiary Referral Center
Kyung Su Kim, Ji Hyun Chang, Noorie Choi, Han-Soo Kim, Ilkyu Han, Kyung Chul Moon, Il Han Kim, Hak Jae Kim
Cancer Res Treat. 2016;48(2):650-657.   Published online September 9, 2015
DOI: https://doi.org/10.4143/crt.2015.171
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to report on the incidence and the experience in management of radiation-induced sarcoma (RIS) at a large single center in Korea for 15 years.
Materials and Methods
We retrospectively reviewed the sarcoma registry of a large institution from January 2000 to April 2014.
Results
Out of the 3,674 patients listed in the registry, 33 patients (0.9%) diagnosed with RIS were identified. The median latency of RIS was 12.1 years. The number of cases of RIS increased from four cases in the years 2000-2003 to 14 cases in the years 2012-2014. The most common histology was osteosarcoma (36.4%). The median follow-up period was 23.1 months, the median overall survival (OS) of all patients was 2.9 years, and their 5-year survival rate was 44.7%. Univariate and multivariate analyses showed association of the age at diagnosis (p=0.01) and the treatment aim (p=0.001) with the OS. The median OS and the 5-year survival rate of patients treated with curative surgery (n=19) were 9.6 years and 65%, respectively, and of the conservatively treated patients, 0.7 years and 0% (n=14). Re-irradiation was delivered to nine patients, and radiation toxicity was observed in five patients.
Conclusion
In this study, RIS accounted for 0.9% of the cases of sarcoma, with increasing incidence. Despite the association of curative resection with increased survival, it could be applied to only 58% of the patients. Considering the limited treatment options for RIS, conduct of a genetic study to identify the underlying mechanism of RIS is needed.

Citations

Citations to this article as recorded by  
  • Radiation-induced osteosarcoma in the head and neck region: Case report and literature review
    Iara Vieira Ferreira, Marcelo Elias Schempf Cattan, Carlos Takahiro Chone, Arthur Antolini, Erika Said Abu Egal, Albina Altemani, Fernanda Viviane Mariano
    Oral Oncology.2025; 162: 107216.     CrossRef
  • A bone tumor‐like chest wall mass lesion with pathological rib fractures observed 13 years after lung stereotactic body radiotherapy: A case report
    Masaki Matsuda, Jiro Ichikawa, Takafumi Komiyama, Kojiro Onohara, Masahide Saito, Hikaru Nemoto, Mizuki Kubota, Hiroshi Onishi
    Thoracic Cancer.2024; 15(26): 1912.     CrossRef
  • The role of perioperative treatment in radiation-associated soft tissue sarcomas
    Konrad Zasadziński, Mateusz Jacek Spałek
    Oncologie.2024; 26(6): 1065.     CrossRef
  • Clinical and Pathologic Characterization of 94 Radiation-Associated Sarcomas: Our Institutional Experience
    Erica Y. Kao, Abbye E. McEwen, James K. Aden, Stephanie K. Schaub, Robert W. Ricciotti, Jose G. Mantilla
    International Journal of Surgical Pathology.2023; 31(5): 532.     CrossRef
  • Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study
    Mauricio Fernando Ribeiro, Hagit Peretz Soroka, Zainab Bhura, Ian Hirsch, Jay Wunder, Peter Ferguson, Kim Tsoi, Savtaj Brar, Rebecca Gladdy, Carol Swallow, Peter Chung, Charles Catton, Philip Wong, Geoffrey Watson, Albiruni Ryan Abdul Razak, Abha A. Gupta
    Therapeutic Advances in Medical Oncology.2023;[Epub]     CrossRef
  • Treatment and Outcomes of Radiation-Induced Soft Tissue Sarcomas of the Extremities and Trunk—A Systematic Review of the Literature
    Maria L. Inchaustegui, Kelly Kon-Liao, Kim Ruiz-Arellanos, George Aquilino E. Silva, Marcos R. Gonzalez, Juan Pretell-Mazzini
    Cancers.2023; 15(23): 5584.     CrossRef
  • Temporary Knockdown of p53 During Focal Limb Irradiation Increases the Development of Sarcomas
    Andrea R. Daniel, Chang Su, Nerissa T. Williams, Zhiguo Li, Jianguo Huang, Omar Lopez, Lixia Luo, Yan Ma, Lorraine da Silva Campos, Sara R. Selitsky, Jennifer L. Modliszewski, Siyao Liu, Rosa Hernansaiz-Ballesteros, Yvonne M. Mowery, Diana M. Cardona, Cha
    Cancer Research Communications.2023; 3(12): 2455.     CrossRef
  • Treatment related factors associated with the risk of breast radio-induced-sarcoma
    Céline Mirjolet, Ibrahima Diallo, Aurélie Bertaut, Cristina Veres, Paul Sargos, Sylvie Helfre, Marie-Pierre Sunyach, Gilles Truc, Cécile Le Pechoux, Amaury Paumier, Anne Ducassou, Maria Jolnerovski, Juliette Thariat, Michel Lapeyre, Abel Cordoba, Marc-And
    Radiotherapy and Oncology.2022; 171: 14.     CrossRef
  • Radiation-induced osteosarcoma in the pubic bone after proton radiotherapy for prostate cancer: a case report
    Hiroatsu Nakashima, Tetsuro Takatsu, Reiko Imai
    Journal of Rural Medicine.2022; 17(2): 94.     CrossRef
  • Premalignant Conditions of Bone
    Michael D. Eckhoff, Matthew E. Wells, Osvaldo Padilla, Elizabeth M. Polfer, Christopher J. Castagno, Ahmed M. Thabet, Shaimaa Elzamly, Harry L. Wilson, Rajiv Rajani
    JAAOS: Global Research and Reviews.2022;[Epub]     CrossRef
  • Histology-Specific Prognostication for Radiation-Associated Soft Tissue Sarcoma
    Edmund K. Bartlett, Avinash Sharma, Kenneth Seier, Cristina R. Antonescu, Narasimhan P. Agaram, Bhumika Jadeja, Evan Rosenbaum, Ping Chi, Murray F. Brennan, Li-Xuan Qin, Kaled M. Alektiar, Samuel Singer
    JCO Precision Oncology.2022;[Epub]     CrossRef
  • Radiation-induced soft tissue sarcoma of the neck after radiation therapy for Hodgkin's lymphoma: a clinical case
    Nikolai A. Ognerubov, Tatiana S. Antipova
    Journal of Modern Oncology.2022; 24(3): 325.     CrossRef
  • Prognostic Score-Based Stratification Analysis Reveals Universal Benefits of Radiotherapy on Lowering the Risk of Ipsilateral Breast Event for Ductal Carcinoma In Situ Patients with Different Risk Levels
    Libo Yang, Dongli Lu, Yutian Lai, Mengjia Shen, Qiuxiao Yu, Ting Lei, Tianjie Pu, Hong Bu
    Annals of Surgical Oncology.2021; 28(2): 975.     CrossRef
  • Radiation-Induced Sarcomas of the Head and Neck: A Systematic Review
    Andrés Coca-Pelaz, Antti A. Mäkitie, Primož Strojan, June Corry, Avraham Eisbruch, Jonathan J. Beitler, Sandra Nuyts, Robert Smee, Johannes A. Langendijk, William M. Mendenhall, Cesare Piazza, Alessandra Rinaldo, Alfio Ferlito
    Advances in Therapy.2021; 38(1): 90.     CrossRef
  • En bloc resection and reconstruction in patients with advanced recurrent nasopharyngeal carcinoma and radiation-induced sarcoma of the head and neck
    W.-l. Chen, Y.-M. Liu, B. Zhou, R. Chen, Z.-y. Lin, Z.-q. Huang, Z-x. Huang
    International Journal of Oral and Maxillofacial Surgery.2021; 50(6): 711.     CrossRef
  • Incidence of radiation induced sarcoma attributable to radiotherapy in adults: A retrospective cohort study in the SEER cancer registries across 17 primary tumor sites
    Anson Snow, Alexander Ring, Lucas Struycken, Wendy Mack, Melissa Koç, Julie E. Lang
    Cancer Epidemiology.2021; 70: 101857.     CrossRef
  • Radiation-Induced Sarcoma: A Retrospective Population-Based Study Over 34 Years in a Single Institution
    L.B. Callesen, A. Safwat, H.K. Rose, F.B. Sørensen, T. Baad-Hansen, N. Aggerholm-Pedersen
    Clinical Oncology.2021; 33(5): e232.     CrossRef
  • Proliferating trichilemmal tumour of the eyelid in a 7-year-old girl
    Avery Bryan, Susan Kurian, Yan Li, Paige Bundrick
    BMJ Case Reports.2021; 14(2): e237476.     CrossRef
  • Treating radiation-induced sarcoma of the head and neck: A case report
    Yuka Takumi, Kazufumi Obata, Atsushi Kondo, Ryo Miyata, Ayaka Sasaki, Kenichi Takano
    Otolaryngology Case Reports.2021; 19: 100283.     CrossRef
  • Pelvic Radiation-Induced Sarcoma With Rhabdomyoblastic Differentiation Following Treatment of Cervical Cancer
    Shahd S Almohsen, Hala Alnuaim, Alaa A Salim, Haitham Arabi
    Cureus.2021;[Epub]     CrossRef
  • MYC expression has limited utility in the distinction of undifferentiated radiation‐associated sarcomas from sporadic sarcomas and sarcomatoid carcinoma
    Jeffrey K Mito, Xiaohua Qian, Vickie Y Jo, Leona A Doyle
    Histopathology.2020; 77(4): 667.     CrossRef
  • Sarcomas óseos secundarios
    J.-C. Mattei, A. Griffin, P. Ferguson, G. Venton, J. Wunder, A. Rochwerger
    EMC - Aparato Locomotor.2020; 53(4): 1.     CrossRef
  • Sarcomes osseux secondaires
    J.-C. Mattei, A. Griffin, P. Ferguson, G. Venton, J. Wunder, A. Rochwerger
    EMC - Appareil locomoteur.2020; 34(3): 1.     CrossRef
  • Radiation-Associated Sarcomas
    Jeffrey K. Mito, Devarati Mitra, Leona A. Doyle
    Surgical Pathology Clinics.2019; 12(1): 139.     CrossRef
  • A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas
    Jeffrey K. Mito, Devarati Mitra, Constance M. Barysauskas, Adrián Mariño-Enriquez, Elizabeth A. Morgan, Christopher D.M. Fletcher, Chandrajit P. Raut, Elizabeth H. Baldini, Leona A. Doyle
    International Journal of Radiation Oncology*Biology*Physics.2019; 104(2): 425.     CrossRef
  • Osteosarcoma of the jaw – experience at the Medical University Vienna and comparative study with international tumor registries
    Christina Eder-Czembirek, Doris Moser, Simone Holawe, Thomas Brodowicz, Jutta Ries, Irene Sulzbacher, Edgar Selzer
    Clinics.2019; 74: e701.     CrossRef
  • Multifocal superficial rapidly growing postirradiation sarcoma mimicking metastatic carcinoma
    Debasis Gochhait, Priyadarshini Dehuri, Vidhyalakshmi Rangarajan, Neelaiah Siddaraju
    Journal of Mid-life Health.2019; 10(2): 101.     CrossRef
  • Radiation-induced sarcoma in a cat following hypofractionated, palliative intent radiation therapy for large-cell lymphoma
    Matthew R Cook, Michael P Martinez, Joelle M Fenger, Noopur C Desai
    Journal of Feline Medicine and Surgery Open Reports.2019;[Epub]     CrossRef
  • Unique Case Report of a Meningeal Sarcoma Arising during Ongoing Treatment for Progressing Intraparenchymal Glioma
    Richard A. Peterson, Bhavani Kashyap, Pamala A. Pawloski, Anna C. Forsberg, Leah R. Hanson
    Case Reports in Oncological Medicine.2019; 2019: 1.     CrossRef
  • Radiation‐associated sarcoma after breast cancer in a nationwide population: Increasing risk of angiosarcoma
    Samuli H. Salminen, Mika M. Sampo, Tom O. Böhling, Laura Tuomikoski, Maija Tarkkanen, Carl P. Blomqvist
    Cancer Medicine.2018; 7(9): 4825.     CrossRef
  • Radiation-Associated Sarcoma of the Neck: Case Series and Systematic Review
    Lawrence Williams, Lyubov Tmanova, Wojciech K. Mydlarz, Brandi Page, Jeremy D. Richmon, Harry Quon, Nicole C. Schmitt
    Annals of Otology, Rhinology & Laryngology.2018; 127(10): 735.     CrossRef
  • Radiation‐associated neoplasia: clinical, pathological and genomic correlates
    Lynette M Sholl, Justine A Barletta, Jason L Hornick
    Histopathology.2017; 70(1): 70.     CrossRef
  • Magnetic Resonance Imaging of Soft Tissue Masses
    Aaron D. Fain, Francesca D. Beaman
    Seminars in Roentgenology.2017; 52(4): 227.     CrossRef
  • Characteristics of tumors that have developed in mice injected with syngenic irradiated mesenchymal stem cells of bone marrow
    E. Yu. Moskaleva, E. S. Zhorova, Yu. P. Semochkina, A. V. Rodina, O. V. Vysotskaya, A. I. Glukhov, A. A. Chukalova, G. A. Posypanova, V. P. Saprykin
    Cell and Tissue Biology.2017; 11(5): 381.     CrossRef
  • Case Report: Primary De Novo Sarcoma In Transplant Pancreas Allograft
    S. Nagaraju, S.J. Grethlein, S. Vaishnav, A.A. Sharfuddin, J.A. Powelson, J.A. Fridell
    Transplantation Proceedings.2017; 49(10): 2352.     CrossRef
  • Radiation-induced osteosarcoma of the maxilla and mandible after radiotherapy for nasopharyngeal carcinoma
    Lie-Qiang Liao, Hong-Hong Yan, Jun-Hao Mai, Wei-Wei Liu, Hao Li, Zhu-Ming Guo, Zong-Yuan Zeng, Xue-Kui Liu
    Chinese Journal of Cancer.2016;[Epub]     CrossRef
  • 14,524 View
  • 198 Download
  • 29 Web of Science
  • 36 Crossref
Close layer
The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo
Keun-Yong Eom, Bong Jun Cho, Eun Jung Choi, Jin-Ho Kim, Eui Kyu Chie, Hong-Gyun Wu, Il Han Kim, Sun Ha Paek, Jae-Sung Kim, In Ah Kim
Cancer Res Treat. 2016;48(2):687-697.   Published online June 4, 2015
DOI: https://doi.org/10.4143/crt.2014.320
AbstractAbstract PDFPubReaderePub
Purpose
We investigated the effect of chemoradiotherapy with PP2 and temozolomide (TMZ) on malignant glioma cells using clonogenic assays and in vivo brain tumor model.
Materials and Methods
The effect of PP2 on radiosensitivity of U251 and T98G cells was investigated using clonogenic assays. The expression of E-cadherin, matrix metalloproteinases 2 (MMP2), Ephrin type-A receptor 2 (EphA2), and vascular endothelial growth factor (VEGF) was measured by Western blotting and an accumulation of γH2AX foci 6 hours after radiotherapy was measured after PP2 treatment. The effect of PP2 on migration, invasion, and vasculogenic mimicry formation (VMF) of U251 cells was evaluated. In an orthotopical brain tumor model with U251 cells, PP2 was injected intraperitoneally with or without oral TMZ before, during and after whole brain radiotherapy. Bioluminescence images were taken to visualize in vivo tumors and immunohistochemical staining of VEGF, CD31, EphA2, and hypoxia-inducible factor 1a was performed.
Results
PP2 increased radiosensitivity of U251 and T98G cells without decreasing survival of normal human astrocytes. Chemoradiotherapy with PP2 and TMZ resulted in increased accumulation of γH2AX foci. PP2 induced overexpression of E-cadherin and suppression of MMP2, VEGF, and EphA2. PP2 also compromised invasion, migration, and VMF of U251 cells. In brain tumors, chemoradiotherapy with PP2 and TMZ decreased tumor volume best, but not statistically significantly compared with chemoradiotherapy with TMZ. The expression of VEGF and CD31 was suppressed in PP2-treated tumors.
Conclusion
PP2 enhances radiosensitivity of malignant glioma cells and suppresses invasion and migration of U251 cells. Chemoradiotherapy with PP2 and TMZ resulted in non-significant tumor volume decrease.

Citations

Citations to this article as recorded by  
  • Dihydroartemisinin inhibits EphA2/PI3K/Akt pathway-mediated malignant behaviors and vasculogenic mimicry in glioma stem cells
    Huangde Fu, Shengtian Wu, Hechun Shen, Kai Luo, Zhongxiang Huang, Nankun Lu, Yaolin Li, Qian Lan, Yishun Xian
    Heliyon.2025; 11(3): e42095.     CrossRef
  • MiR 329/449 Suppresses Cell Proliferation, Migration and Synergistically Sensitizes GBM to TMZ by Inhibiting Src/FAK, NF-kB, and Cyclin D1 Activity
    Megan Mendieta, Mehrdad Bandegi, Ezgi Biltekin, Yasemin M. Akay, Bulent Ozpolat, Metin Akay
    International Journal of Molecular Sciences.2025; 26(12): 5533.     CrossRef
  • c-Src inhibitor PP2 inhibits head and neck cancer progression through regulation of the epithelial–mesenchymal transition
    SunYoung Lee, Sunjung Park, Jae-Sung Ryu, Jaegu Kang, Ikhee Kim, Sumin Son, Bok-Soon Lee, Chul-Ho Kim, Yeon Soo Kim
    Experimental Biology and Medicine.2023; 248(6): 492.     CrossRef
  • Molecular Targeted Therapies in Glioblastoma Multiforme: A Systematic Overview of Global Trends and Findings
    Emir Begagić, Ragib Pugonja, Hakija Bečulić, Amila Čeliković, Lejla Tandir Lihić, Samra Kadić Vukas, Lejla Čejvan, Rasim Skomorac, Edin Selimović, Belma Jaganjac, Fatima Juković-Bihorac, Aldin Jusić, Mirza Pojskić
    Brain Sciences.2023; 13(11): 1602.     CrossRef
  • Hemorrhage in brain tumor – An unresolved issue
    Robert P. Ostrowski, Zhaohui He, Emanuela B. Pucko, Ewa Matyja
    Brain Hemorrhages.2022; 3(2): 98.     CrossRef
  • The interactions of CAP and LYN with the insulin signaling transducer CBL play an important role in polycystic ovary syndrome
    Haoran Shen, Xiao Xu, Zhongpeng Fu, Chengjie Xu, Yao Wang
    Metabolism.2022; 131: 155164.     CrossRef
  • Identification of four key prognostic genes and three potential drugs in human papillomavirus negative head and neck squamous cell carcinoma
    Guocai Tian, You Fu, Dahe Zhang, Jiang Li, Zhiyuan Zhang, Xi Yang
    Cancer Cell International.2021;[Epub]     CrossRef
  • Intracellular Progesterone Receptor and cSrc Protein Working Together to Regulate the Activity of Proteins Involved in Migration and Invasion of Human Glioblastoma Cells
    Claudia Bello-Alvarez, Aylin Del Moral-Morales, Aliesha González-Arenas, Ignacio Camacho-Arroyo
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Synergistic Tumoricidal Effects of Alpha-Lipoic Acid and Radiotherapy on Human Breast Cancer Cells via HMGB1
    Hoon Sik Choi, Jin Hyun Kim, Si Jung Jang, Jeong Won Yun, Ki Mun Kang, Hojin Jeong, In Bong Ha, Bae Kwon Jeong
    Cancer Research and Treatment.2021; 53(3): 685.     CrossRef
  • Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications
    Raúl Ortiz, Gloria Perazzoli, Laura Cabeza, Cristina Jiménez-Luna, Raquel Luque, Jose Prados, Consolación Melguizo
    Current Neuropharmacology.2021; 19(4): 513.     CrossRef
  • SRC Tyrosine Kinase Inhibitor and X-rays Combined Effect on Glioblastoma Cell Lines
    Filippo Torrisi, Luigi Minafra, Francesco P. Cammarata, Gaetano Savoca, Marco Calvaruso, Nunzio Vicario, Laura Maccari, Elodie A. Pérès, Hayriye Özçelik, Myriam Bernaudin, Lorenzo Botta, Giorgio Russo, Rosalba Parenti, Samuel Valable
    International Journal of Molecular Sciences.2020; 21(11): 3917.     CrossRef
  • SRC Kinase in Glioblastoma: News from an Old Acquaintance
    Claudia Cirotti, Claudia Contadini, Daniela Barilà
    Cancers.2020; 12(6): 1558.     CrossRef
  • Development of a patient-derived xenograft model of glioblastoma via intravitreal injection in mice
    Jooyoung Lee, Dong Hyun Jo, Jin Hyoung Kim, Chang Sik Cho, Jiwon Esther Han, Yona Kim, Hyoungwoo Park, Seung Ho Yoo, Young Suk Yu, Hyo Eun Moon, Hye Ran Park, Dong Gyu Kim, Jeong Hun Kim, Sun Ha Paek
    Experimental & Molecular Medicine.2019; 51(4): 1.     CrossRef
  • Antagonism between the RNA-binding protein Musashi1 and miR-137 and its potential impact on neurogenesis and glioblastoma development
    Mitzli X. Velasco, Adam Kosti, Gabriela D.A. Guardia, Marcia C. Santos, Allison Tegge, Mei Qiao, Bruna R.S. Correa, Greco Hernández, Erzsebet Kokovay, Pedro A.F. Galante, Luiz O.F. Penalva
    RNA.2019; 25(7): 768.     CrossRef
  • Suppression of the Smurf1 Expression Inhibits Tumor Progression in Gliomas
    Hao Chang, Jingning Zhang, Zengli Miao, Yasuo Ding, Xing Xu, Xudong Zhao, Peng Xu, Qing Wang, Yuchang Lin
    Cellular and Molecular Neurobiology.2018; 38(2): 421.     CrossRef
  • ZEB1‐mediated vasculogenic mimicry formation associates with epithelial–mesenchymal transition and cancer stem cell phenotypes in prostate cancer
    Hua Wang, Bin Huang, Bai Mou Li, Kai Yuan Cao, Chen Qiang Mo, Shuang Jian Jiang, Jin Cheng Pan, Zong Ren Wang, Huan Yi Lin, Dao Hu Wang, Shao Peng Qiu
    Journal of Cellular and Molecular Medicine.2018; 22(8): 3768.     CrossRef
  • CD59 is a potential biomarker of esophageal squamous cell carcinoma radioresistance by affecting DNA repair
    Yuzhen Zhou, Li Chu, Qi Wang, Weixing Dai, Xiaozhou Zhang, Jianfeng Chen, Ling Li, Peipei Ding, Long Zhang, Hongyu Gu, Luying Li, Xinyue Lv, Wei Zhang, Danlei Zhou, Pingzhao Zhang, Guoxiang Cai, Kuaile Zhao, Weiguo Hu
    Cell Death & Disease.2018;[Epub]     CrossRef
  • KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma
    Michael J. Ciesielski, Yahao Bu, Stephan A. Munich, Paola Teegarden, Michael P. Smolinski, James L. Clements, Johnson Y. N. Lau, David G. Hangauer, Robert A. Fenstermaker
    Journal of Neuro-Oncology.2018; 140(3): 519.     CrossRef
  • The function and mechanism of preactivated thiomers in triggering epithelial tight junctions opening
    Yang Zhang, Shurong Zhou, Feiyang Deng, Xianhui Chen, Xing Wang, Yaoqi Wang, Hua Zhang, Wenbing Dai, Bing He, Qiang Zhang, Xueqing Wang
    European Journal of Pharmaceutics and Biopharmaceutics.2018; 133: 188.     CrossRef
  • The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
    Fei Shi, Jinying Zhang, Hongyu Liu, Liangliang Wu, Hongyu Jiang, Qiyan Wu, Tianyi Liu, Meiqing Lou, Hao Wu
    Oncotarget.2018; 9(1): 706.     CrossRef
  • Mechanism of the Antitumor and Radiosensitizing Effects of a Manganese Porphyrin, MnHex-2-PyP
    Sung-Won Shin, Changhoon Choi, Ga-Haeng Lee, Arang Son, Su-Hyeon Kim, Hee Chul Park, Ines Batinic-Haberle, Won Park
    Antioxidants & Redox Signaling.2017; 27(14): 1067.     CrossRef
  • Combination of sonodynamic with temozolomide inhibits C6 glioma migration and promotes mitochondrial pathway apoptosis via suppressing NHE-1 expression
    Lei Chen, Damin Cong, Yongzhe Li, Dan Wang, Qingsong Li, Shaoshan Hu
    Ultrasonics Sonochemistry.2017;[Epub]     CrossRef
  • Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells
    Tosol Yu, Bong Jun Cho, Eun Jung Choi, Ji Min Park, Dan Hyo Kim, In Ah Kim
    Oncotarget.2016; 7(48): 79089.     CrossRef
  • RND3 promotes Snail 1 protein degradation and inhibits glioblastoma cell migration and invasion
    Baohui Liu, Huimin Dong, Xi Lin, Xiangsheng Yang, Xiaojing Yue, Jian Yang, Yuntao Li, Liquan Wu, Xiaonan Zhu, Shenqi Zhang, Daofeng Tian, Junmin Wang, Qiang Cai, Shanping Mao, Qianxue Chen, Jiang Chang
    Oncotarget.2016; 7(50): 82411.     CrossRef
  • 13,989 View
  • 171 Download
  • 25 Web of Science
  • 24 Crossref
Close layer
Extra-cranial Malignant Rhabdoid Tumor in Children: A Single Institute Experience
Che Ry Hong, Hyoung Jin Kang, Hee Young Ju, Ji Won Lee, Hyery Kim, Sung-Hye Park, Il Han Kim, Kyung Duk Park, Hee Young Shin
Cancer Res Treat. 2015;47(4):889-896.   Published online January 2, 2015
DOI: https://doi.org/10.4143/crt.2013.176
AbstractAbstract PDFPubReaderePub
Purpose
Malignant rhabdoid tumor (MRT) is a rare and highly aggressive tumor that affects young children. Due to its extreme rarity, most of the available data are based on retrospective case series. To add to the current knowledge of this disease, we reviewed the patients treated for extra-cranial MRT in our institute. Materials and Methods A retrospective medical record review was conducted on children treated for pathologically confirmed extra-cranial MRT at Seoul National University Children’s Hospital between January 2003 and May 2013. Results Eleven patients (7 boys, 4 girls) were diagnosed with extra-cranial MRT at a median age of 9 months old. INI1 staining was important in the pathological confirmation. Six patients (55%) had renal MRT and five (45%) had soft tissue MRT. Five patients (45%) had metastases at diagnosis. All patients underwent chemotherapy, eight patients (73%) underwent surgery, six patients (55%) received therapeutic radiotherapy, and four patients (36%) underwent high dose chemotherapy with autologous stem cell rescue (HDCT/ASCR) with melphalan, etoposide, and carboplatin. Five patients (45%) died of disease following progression (n=3) or relapse (n=2), however, there was no treatment related mortality. The overall survival of the cohort was 53.0% and the event-free survival was 54.5% with a median follow-up duration of 17.8 months (range, 2.3 to 112.3 months). Conclusion Extra-cranial MRT is still a highly aggressive tumor in young children. However, the improved survival of our cohort is promising and HDCT/ASCR with melphalan, etoposide, and carboplatin may be a promising treatment option.

Citations

Citations to this article as recorded by  
  • A Review of Wilms Tumor
    Valeria Smith, Andrew Wahba, Murali Chintagumpala, Priya Mahajan
    Pediatrics in Review.2025; 46(4): 206.     CrossRef
  • Extracranial malignant rhabdoid tumors in children: high mortality even with the help of an aggressive clinical approach
    Siqi Xie, Yuanyuan Fang, Yingying Yang, Lan Liu, Jianxi Bai, Sheng Lin, Bing Zhang, Yifan Fang
    European Journal of Pediatrics.2023; 183(2): 557.     CrossRef
  • Infantile Extracranial Rhabdoid Tumor of the Scalp
    Sura Al Rawabdeh, Deifallah Alsharari, Hayat Khasawneh, Ola M. Al Waqfi, Qamar Yaser Malabeh, Hiathem Abu Alhaija, Raed Mohammad Aljubour, Hamzeh M. Alkhawaldeh, Pablo Fernandez Pe as
    Case Reports in Medicine.2021; 2021: 1.     CrossRef
  • Pharmacokinetics of high-dose carboplatin in children undergoing high-dose chemotherapy and autologous stem cell transplantation with BSA-based dosing
    Che Ry Hong, Hyoung Jin Kang, Seol Ju Moon, Jaeseong Oh, Kyung Taek Hong, Jung Yoon Choi, Kyung-Sang Yu, Hee Young Shin
    Bone Marrow Transplantation.2020; 55(1): 137.     CrossRef
  • Successful Treatment of Extra‐Renal Noncerebral Rhabdoid Tumors with VIDE
    Naoko Yasui, Akihiko Yoshida, Eisuke Kobayashi, Fumihiko Nakatani, Hiroshi Kawamoto
    Pediatric Blood & Cancer.2016; 63(2): 352.     CrossRef
  • 15,069 View
  • 151 Download
  • 6 Web of Science
  • 5 Crossref
Close layer
In Vitro and In Vivo Radiosensitizing Effect of Valproic Acid on Fractionated Irradiation
Eui Kyu Chie, Jin Hee Shin, Jin Ho Kim, Hak Jae Kim, In Ah Kim, Il Han Kim
Cancer Res Treat. 2015;47(3):527-533.   Published online November 24, 2014
DOI: https://doi.org/10.4143/crt.2014.026
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted in order to validate the radiosensitization effect of valproic acid, a biologically available histone deacetylase inhibitor, for fractionated radiation.
Materials and Methods
Radiosensitization effect of valproic acid was tested for the A549 cell line and U87MG cell line in vitro. Fractionated irradiation of 12 Gy in four fractions was administered on D2-5 with valproic acid, 150 mg/Kg, ip, bid for six consecutive days (D1-6) to A549 and U87MG tumors implanted in BALB/c-nude mice. A growth delay curve was formulated.
Results
Radiosensitization effect of valproic acid was found for both cell lines; A549 at 1.5 mM and 3.0 mM concentration and U87MG at 3.0 mM concentration. In growth delay analysis, a statistically significant radiosensitization effect was observed for both tumors (p < 0.001 for both tumors). Difference for change in slope for control and valproic acid versus radiotherapy and radiotherapy plus valproic acid showed borderline significance for the U87MG cell line (p=0.065), indicating beyond additive effect, whereas this difference was statistically insignificant for A549 tumor (p=0.951), indicating additive effect.
Conclusion

Results
of this study indicate that a radiosensitizing effect for fractionated radiotherapy of valproic acid for A549 and U87MG tumors in vivo is evident and that it may be more than additive for U87MG tumors. Further exploitation of histone deacetylase inhibitors in clinical trials is warranted.

Citations

Citations to this article as recorded by  
  • Anti-epileptic drug use during adjuvant chemo-radiotherapy is associated with poorer survival in patients with glioblastoma: A nationwide population-based cohort study
    Peng-Yi Lee, Yu-Ting Wei, Kun-San Clifford Chao, Chin-Nan Chu, Wen-Hui Chung, Ti-Hao Wang*
    Journal of Cancer Research and Therapeutics.2024; 20(2): 555.     CrossRef
  • Valproic acid as a radio-sensitizer in glioma: A systematic review and meta-analysis
    Jessica K Sullivan, Paul P Fahey, Kinglsey E Agho, Simon P Hurley, Zhihui Feng, Richard O Day, David Lim
    Neuro-Oncology Practice.2023; 10(1): 13.     CrossRef
  • The function of histone methylation and acetylation regulators in GBM pathophysiology
    Colin McCornack, Timothy Woodiwiss, Angela Hardi, Hiroko Yano, Albert H. Kim
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Antitumor Activity of Non-thermal Atmospheric Pressure Plasma and Synergistic Effects of Hyperthermia
    TETSUO ADACHI
    Thermal Medicine.2022; 38(1): 1.     CrossRef
  • Epigenetic-Like Stimulation of Receptor Expression in SSTR2 Transfected HEK293 Cells as a New Therapeutic Strategy
    Joerg Kotzerke, Dorothee Buesser, Anne Naumann, Roswitha Runge, Lisa Huebinger, Andrea Kliewer, Robert Freudenberg, Claudia Brogsitter
    Cancers.2022; 14(10): 2513.     CrossRef
  • Molecular Mechanisms Underlying Cellular Responses to the Loading of Non-thermal Atmospheric Pressure Plasma-activated Solutions
    Tetsuo Adachi
    YAKUGAKU ZASSHI.2021; 141(10): 1185.     CrossRef
  • Ability of plasma-activated acetated Ringer’s solution to induce A549 cell injury is enhanced by a pre-treatment with histone deacetylase inhibitors
    Tetsuo Adachi, Yumiko Matsuda, Rika Ishii, Tetsuro Kamiya, Hirokazu Hara
    Journal of Clinical Biochemistry and Nutrition.2020; 67(3): 232.     CrossRef
  • Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide
    Yu-Jen Kuo, Yao-Hsu Yang, I-Yun Lee, Pau-Chung Chen, Jen-Tsung Yang, Ting-Chung Wang, Martin Hsiu-Chu Lin, Wei-Hsun Yang, Chun-Yu Cheng, Kuo-Tai Chen, Wei-Chao Huang, Ming-Hsueh Lee
    Medicine.2020; 99(28): e21147.     CrossRef
  • Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead
    Rashmi R. Shah, Peter D. Stonier
    Journal of Clinical Pharmacy and Therapeutics.2019; 44(1): 6.     CrossRef
  • Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation
    Jeong Il Yu, Changhoon Choi, Sung-Won Shin, Arang Son, Ga-Haeng Lee, Shin-Yeong Kim, Hee Chul Park
    Scientific Reports.2017;[Epub]     CrossRef
  • Histone deacetylase inhibitors stimulate the susceptibility of A549 cells to a plasma-activated medium treatment
    Tetsuo Adachi, Ayame Kano, Saho Nonomura, Tetsuro Kamiya, Hirokazu Hara
    Archives of Biochemistry and Biophysics.2016; 606: 120.     CrossRef
  • Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma
    Caroline Happold, Thierry Gorlia, Olivier Chinot, Mark R. Gilbert, L. Burt Nabors, Wolfgang Wick, Stephanie L. Pugh, Monika Hegi, Timothy Cloughesy, Patrick Roth, David A. Reardon, James R. Perry, Minesh P. Mehta, Roger Stupp, Michael Weller
    Journal of Clinical Oncology.2016; 34(7): 731.     CrossRef
  • 11,939 View
  • 108 Download
  • 16 Web of Science
  • 12 Crossref
Close layer
Low-Dose Whole Brain Radiotherapy with Tumor Bed Boost after Methotrexate-Based Chemotherapy for Primary Central Nervous System Lymphoma
Byoung Hyuck Kim, Il Han Kim, Sung-Hye Park, Chul Kee Park, Hee Won Jung, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo
Cancer Res Treat. 2014;46(3):261-269.   Published online July 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.3.261
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to evaluate the outcome of low-dose whole brain radiotherapy (WBRT) with tumor bed boost after methotrexate-based chemotherapy in the management of primary central nervous system lymphoma (PCNSL). Materials and Methods We retrospectively analyzed 64 patients with pathologically proven PCNSL between 2000 and 2011. Methotrexate-based chemotherapy with a median of five cycles was followed by radiotherapy to the whole brain and to the initial tumor bed. The median dose to the whole brain and to the tumor bed was 27 Gy (range, 18 to 36 Gy) and 50.4 Gy (range, 45 to 54 Gy), respectively. Results With a median follow-up period of 27 months, 55 patients (85.9%) achieved complete response (CR). The 5-year overall survival (OS) and progression-free survival (PFS) rates were 52.6% and 39.3%, respectively. In univariate analysis, factors associated with OS were age, performance status, involvement of deep structure, and CR to sequential chemoradiotherapy (CRT). These variables remained as significant factors for OS in multivariate analysis. CR to sequential CRT was the only positive factor associated with PFS (p=0.009). Neurologic toxicity was more common in elderly patients older than 60 years (p=0.025). Conclusion Low-dose WBRT with tumor bed boost after methotrexate-based chemotherapy might be an effective method for management of PCNSL.

Citations

Citations to this article as recorded by  
  • Role of Radiotherapy in PCNSL within the Current Therapeutic Landscape: a Comprehensive Review
    Min Li, Ran Peng, Fang Bao, Hongmei Jing, Hao Wang
    Current Treatment Options in Oncology.2025; 26(6): 486.     CrossRef
  • A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma
    Sara Steffanoni, Teresa Calimeri, Nicoletta Anzalone, Sara Mastaglio, Massimo Bernardi, Andrés JM Ferreri
    Expert Review of Hematology.2022; 15(1): 33.     CrossRef
  • Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse
    Peng Du, Hongyi Chen, Li Shen, Xiao Liu, Xuefan Wu, Lang Chen, Aihong Cao, Daoying Geng
    Current Oncology.2022; 29(9): 6642.     CrossRef
  • Cytoreductive Surgery for Primary Central Nervous System Lymphoma: Is it time to consider extent of resection?
    Shaani Singhal, Ellathios Antoniou, Edward Kwan, Gareth Gregory, Leon T. Lai
    Journal of Clinical Neuroscience.2022; 106: 110.     CrossRef
  • Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy
    Nalee Kim, Do Hoon Lim, Sang Eun Yoon, Seok Jin Kim, Won Seog Kim
    Journal of Neuro-Oncology.2021; 154(2): 207.     CrossRef
  • Nanomedicine Applications in Treatment of Primary Central Nervous System Lymphoma: Current State of the Art
    Mengyao Wang, Ying Qu, Danrong Hu, Ting Niu, Zhiyong Qian
    Journal of Biomedical Nanotechnology.2021; 17(8): 1459.     CrossRef
  • Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma
    Tae Hoon Lee, Joo Ho Lee, Ji Hyun Chang, Sung-Joon Ye, Tae Min Kim, Chul-Kee Park, Il Han Kim, Byoung Hyuck Kim, Chan Woo Wee
    Radiation Oncology Journal.2020; 38(1): 35.     CrossRef
  • Advances and challenges in the treatment of primary central nervous system lymphoma
    Hua Yang, Yang Xun, Anping Yang, Fang Liu, Hua You
    Journal of Cellular Physiology.2020; 235(12): 9143.     CrossRef
  • Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy
    Jun Su Park, Do Hoon Lim, Yong Chan Ahn, Won Park, Seok Jin Kim, Won Seog Kim, Kihyun Kim
    Japanese Journal of Clinical Oncology.2017; 47(11): 995.     CrossRef
  • Role of radiation therapy in primary central nervous system lymphoma
    Hyeon Kang Koh, Il Han Kim, Tae Min Kim, Do Hoon Lim, Dongryul Oh, Jae Ho Cho, Woo-Chul Kim, Jin Hee Kim, Woong-Ki Chung, Bae-Kwon Jeong, Ki Mun Kang, Semie Hong, Chang-Ok Suh, In Ah Kim
    Journal of Neuro-Oncology.2017; 135(3): 629.     CrossRef
  • 12,908 View
  • 78 Download
  • 11 Web of Science
  • 10 Crossref
Close layer
Editorial
Editorial: New Systems Introduced for the Betterment of Our Journal
Il Han Kim
Cancer Res Treat. 2014;46(1):1-1.   Published online January 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.1.1
AbstractAbstract PDFPubReaderePub
No abstract available.

Citations

Citations to this article as recorded by  
  • Adaptive radiation therapy in head and neck cancer for clinical practice: state of the art and practical challenges
    Ovidiu Veresezan, Idriss Troussier, Alexis Lacout, Sarah Kreps, Sophie Maillard, Aude Toulemonde, Pierre-Yves Marcy, Florence Huguet, Juliette Thariat
    Japanese Journal of Radiology.2017; 35(2): 43.     CrossRef
  • 7,565 View
  • 45 Download
  • 1 Crossref
Close layer
Original Article
Sequence-Dependent Radiosensitization of Histone Deacetylase Inhibitors Trichostatin A and SK-7041
Jin Ho Kim, Il Han Kim, Jin Hee Shin, Hak Jae Kim, In Ah Kim
Cancer Res Treat. 2013;45(4):334-342.   Published online December 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.4.334
AbstractAbstract PDFPubReaderePub
PURPOSE
This preclinical study is to determine whether the capacity of histone deacetylase (HDAC) inhibitors to enhance radiation response depends on temporal sequences of HDAC inhibition and irradiation.
MATERIALS AND METHODS
The effects of HDAC inhibitors trichostatin A (TSA) and SK-7041 on radiosensitivity in human lung cancer cells were examined using a clonogenic assay, exposing cells to HDAC inhibitors in various sequences of HDAC inhibition and radiation. We performed Western blot of acetylated histone H3 and flow cytometry to analyze cell cycle phase distribution.
RESULTS
TSA and SK-7041 augmented radiation cell lethality in an exposure time-dependent manner when delivered before irradiation. The impact of TSA and SK-7041 on radiosensitivity rapidly diminished when HDAC inhibition was delayed after irradiation. Radiation induced the acetylation of histone H3 in cells exposed to TSA, while irradiation alone had no effect on the expression of acetylated histone H3 in TSA-naive cells. Preirradiation exposure to TSA abrogated radiation-induced G2/M-phase arrest. When delivered after irradiation, TSA had no effect on the peak of radiation-induced G2/M-phase arrest.
CONCLUSION
TSA and SK-7041 enhances radiosensitivity only when delivered before irradiation. Unless proven otherwise, it seems prudent to apply scheduling including preirradiation HDAC inhibition so that maximal radiosensitization is obtained.

Citations

Citations to this article as recorded by  
  • Mechanistic Sequence of Histone Deacetylase Inhibitors and Radiation Treatment: An Overview
    Elsie Neo Seane, Shankari Nair, Charlot Vandevoorde, Anna Joubert
    Pharmaceuticals.2024; 17(5): 602.     CrossRef
  • Investigation of geroprotective and radioprotective effects of berberine and trichostatin A on the model of Drosophila melanogaster
    N. Ulyasheva, E. Proshkina, M. Shaposhnikov, A. Moskalev
    Proceedings of the Komi Science Centre of the Ural Division of the Russian Academy of Sciences.2023; 0(6): 93.     CrossRef
  • Low Dose of Trichostatin A Improves Radiation Resistance by Activating Akt/Nrf2-Dependent Antioxidation Pathway in Cancer Cells
    Fengqiu Zhang, Changsheng Shao, Zhu Chen, Yalin Li, Xumiao Jing, Qing Huang
    Radiation Research.2021;[Epub]     CrossRef
  • Time-sequential change in immune-related gene expression after irradiation in glioblastoma: next-generation sequencing analysis
    Yi-Jun Kim, Kwangsoo Kim, Soo Yeon Seo, Juyeon Yu, Il Han Kim, Hak Jae Kim, Chul-Kee Park, Kye Hwa Lee, Junjeong Choi, Myung Seon Song, Jin Ho Kim
    Animal Cells and Systems.2021; 25(4): 245.     CrossRef
  • Is level of acetylation directly correlated to radiation sensitivity of cancer cell?
    Fengqiu Zhang, Zhu Chen, Changsheng Shao, Qing Huang
    Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis.2019; 813: 13.     CrossRef
  • Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro
    Hyeon Kang Koh, Soo Yeon Seo, Jin Ho Kim, Hak Jae Kim, Eui Kyu Chie, Seung-Ki Kim, Il Han Kim
    Cancer Research and Treatment.2019; 51(2): 696.     CrossRef
  • Psammaplin A-Modified Novel Radiosensitizers for Human Lung Cancer and Glioblastoma Cells
    Chan Woo Wee, Jin Ho Kim, Hak Jae Kim, Hyun-Cheol Kang, Soo Youn Suh, Beom Soo Shin, Eunsook Ma, Il Han Kim
    Journal of Radiation Protection and Research.2019; 44(1): 15.     CrossRef
  • Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization
    Jin Ho Kim, Sung Ho Moon, Mina No, Jae Jin Kim, Eun Jung Choi, Bong Jun Cho, Jae Sung Kim, Il Han Kim, In Ah Kim
    Cancer Research and Treatment.2016; 48(3): 1130.     CrossRef
  • 12,893 View
  • 48 Download
  • 6 Web of Science
  • 8 Crossref
Close layer
Editorial
New Step of Joint Publication with the Korean Association for Clinical Oncology
Il Han Kim
Cancer Res Treat. 2012;44(2):73-73.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.73
AbstractAbstract PDFPubReaderePub
No abstract available.
  • 10,024 View
  • 35 Download
Close layer
Original Articles
The Role of Radiotherapy in the Treatment of Newly Diagnosed Supratentorial Low-grade Oligodendrogliomas: Comparative Analysis with Immediate Radiotherapy versus Surgery Alone
Hyun-Cheol Kang, Il Han Kim, Keun-Yong Eom, Jin Ho Kim, Hee-Won Jung
Cancer Res Treat. 2009;41(3):132-137.   Published online September 28, 2009
DOI: https://doi.org/10.4143/crt.2009.41.3.132
AbstractAbstract PDFPubReaderePub
Purpose

The purpose of this study was to evaluate the role of immediate postoperative radiotherapy (RT) in adult patients with a low-grade oligodendroglioma (LODG).

Materials and Methods

A total of 74 patients, older than 15 years, were treated in our institution between April 1990 and March 2006 for newly diagnosed LODGs. After surgery, 43 patients were treated with immediate RT with a total dose of 54~55.8 Gy with 1.8 Gy fractions (RT group) and 31 patients were followed with no adjuvant RT (OP group). All patients were closely observed until tumor progression or death with frequent work-ups including neurological examinations and MRI. Primary endpoints were overall survival and progression-free survival. The median follow-up duration of survivors was 6.2 years in the RT group and 5.8 years in the OP group.

Results

Median progression-free survival was 13.2 years in the RT group and 4.6 years in the OP group; multivariate analysis confirmed improved outcome with the use of immediate RT (hazard ratio, 0.22; 95% confidence interval-CI, 0.09~0.55; p<0.001). Median overall survival was 14.9 years in the RT group and 9.8 years in the OP group; the use of adjuvant RT was also associated with a trend toward better overall survival after immediate RT based on multivariate analysis (hazard ratio, 0.3; 95% CI, 0.08~1.17; p=0.082). No severe RT related complications were observed.

Conclusion

Immediate RT following surgery appears to be an effective treatment modality for supratentorial LODGs. However, the potential benefit of adjuvant RT for overall survival needs to be tested prospectively in the future.

Citations

Citations to this article as recorded by  
  • A systematic review and meta-analysis informing the role of adjuvant radiotherapy (RT) in Grade 2 and 3 oligodendroglioma
    Zhi Xuan Ng, Eng Siew Koh, Shing Fung Lee, Char Loo Tan, Kejia Teo, Andrea Wong, Simon S. Lo, Balamurugan Vellayappan
    Journal of Clinical Neuroscience.2024; 126: 247.     CrossRef
  • Oligodendrogliomas in Children: Clinical Experiences With 20 Patients
    Chieh-Tsai Wu, Pei-Kwei Tsay, Tang-Her Jaing, Shih-Hsiang Chen, Chen-Kan Tseng, Shih-Ming Jung
    Journal of Pediatric Hematology/Oncology.2016; 38(7): 555.     CrossRef
  • Oligodendroglial Tumors
    Kurt A. Jaeckle
    Seminars in Oncology.2014; 41(4): 468.     CrossRef
  • Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy
    Yasuo Iwadate, Tomoo Matsutani, Yuzo Hasegawa, Natsuki Shinozaki, Yoshinori Higuchi, Naokatsu Saeki
    Journal of Neuro-Oncology.2011; 102(3): 443.     CrossRef
  • 9,020 View
  • 52 Download
  • 4 Crossref
Close layer
Clinical Results of Chemotherapy based Treatment in Retinoblastoma Patients: A Single Center Experience
Hyery Kim, Ji Won Lee, Hyoung Jin Kang, Hyeon Jin Park, Yoon Yi Kim, Hee Young Shin, Young Suk Yu, Il Han Kim, Hyo Seop Ahn
Cancer Res Treat. 2008;40(4):164-171.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.164
AbstractAbstract PDFPubReaderePub
Purpose

Retinoblastoma is the most common intraocular malignancy in children. Since the 1990s, chemotherapy was indicated for intraocluar disease to reduce the frequency of enucleation and spare the complications associated with external beam radiation. In this study, we analyzed treatment results of retinoblastoma in our institute.

Materials and Methods

Datas from children diagnosed with retinoblastoma and treated at Seoul National University Children's Hospital between 1986 and 2008 were analyzed retrospectively. We utilized cyclophosphamide, vincristine, adriamycin, and methotrexate (CVAM) for OPD-based adjuvant chemotherapy. From 1990, primary chemotherapy was administered to patients with intraocular disease for eyeball-saving and patients received a combination of etoposide, vincristine, cisplatin (or ifosfamide) as a moderately intensive regimen, or a combination of cisplatin, doxorubicin, etoposide, and cycophosphamide (CDEC) as a highly intensive regimen.

Results

One hundred eighteen children were analyzed. There were 68 unilateral and 50 bilateral diseases. The median age at diagnosis was 1 year and Reese-Ellsworth stage V was the most common stage at the time of diagnosis. All patients were treated by chemotherapy-based multimodality methods, and primary chemotherapy was administered to 80 patients. The 10-year overall and event-free survival rate of all patients were 93.9% and 91.6%, respectively. Two patients who died were in the CDEC regimen group, but there was no significant statistical difference in survival rates by chemotherapy regimens. Fifty-six of 114 eyeballs were saved after primary chemotherapy-based treatment, and the eyeball-saving rate was 49.1%. Six patients relapsed after enucleation and 2 patients were treated successfully after autologous PBSCT. Osteosarcoma occurred in 2 patients as a secondary malignancy, and facial asymmetry after radiotherapy was the most common long-term sequelae.

Conclusions

In this study, the overall and event-free survival rates of retinoblastoma were satisfactory and eye-saving was possible with primary chemotherapy. Development of new chemotherapeutic regimens and a team approach are necessary to improve the eyeball-saving rate.

Citations

Citations to this article as recorded by  
  • The Italian Society for Rheumatology guidelines on reproductive health in patients with rheumatic diseases
    Chiara Crotti, Nicola Ughi, Emanuela Beretta, Antonio Luca Brucato, Greta Carrara, Maria Sole Chimenti, Paola Conigliaro, Francesca Crisafulli, Giovanna Cuomo, Emma Di Poi, Khadija El Auofy, Micaela Fredi, Maria Chiara Gerardi, Maria Gerosa, Ariela Hoxa,
    Reumatismo.2025;[Epub]     CrossRef
  • The Efficacy of Alternate Systemic Intravenous Chemotherapy and Intra-arterial Chemotherapy Approach for Eye Globe Salvage in Retinoblastoma
    Jung Woo Han, Christopher Seungkyu Lee, Seung Min Hahn, Won Kee Ahn, Hyo Sun Kim, Hyeseon Yun, Sung Chul Lee, Byung Moon Kim, Dong Joon Kim, Chuhl Joo Lyu
    Cancer Research and Treatment.2023; 55(1): 270.     CrossRef
  • Global retinoblastoma survival and globe preservation: a systematic review and meta-analysis of associations with socioeconomic and health-care factors
    Emily S Wong, Richard W Choy, Yuzhou Zhang, Wai Kit Chu, Li Jia Chen, Chi Pui Pang, Jason C Yam
    The Lancet Global Health.2022; 10(3): e380.     CrossRef
  • Twenty-Year Retrospective Study of Post-Enucleation Chemotherapy in High-Risk Patients with Unilateral Retinoblastoma
    Yoon Sunwoo, Jung Yoon Choi, Hyun Jin Park, Bo Kyung Kim, Kyung Taek Hong, Sang In Khwarg, Jaemoon Koh, Sung-Hye Park, Dong Hyun Jo, Jeong Hun Kim, Jung-Eun Cheon, Hyoung Jin Kang
    Children.2022; 9(12): 1983.     CrossRef
  • Development of New Solitary Retinoblastoma Tumors during and after Chemotherapy
    Won Jong Choi, Dong Hyun Jo, Hyoung Jin Kang, Hee Young Shin, Young Suk Yu, Jeong Hun Kim
    Korean Journal of Ophthalmology.2021; 35(1): 73.     CrossRef
  • Outcomes of pediatric retinoblastoma treated with ICEV regimen: A single-center study
    Jassada Buaboonnam, Nattee Narkbunnam, Nassawee Vathana, Chayamon Takpradit, Kamon Phuakpet, Bunchoo Pongtanakul, Sasima Tongsai, La-Ongsri Atchaneeyasakul, Kleebsabai Sanpakit
    Pediatric Hematology and Oncology.2019; 36(2): 73.     CrossRef
  • Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”
    Francis L. Munier, Maja Beck-Popovic, Guillermo L. Chantada, David Cobrinik, Tero T. Kivelä, Dietmar Lohmann, Philippe Maeder, Annette C. Moll, Angel Montero Carcaboso, Alexandre Moulin, Paula Schaiquevich, Ciara Bergin, Paul J. Dyson, Susan Houghton, Fra
    Progress in Retinal and Eye Research.2019; 73: 100764.     CrossRef
  • Outcomes of Proton Beam Radiation Therapy for Retinoblastoma With Vitreous Seeds
    Eun Hye Jung, Jeong Hun Kim, Joo Young Kim, Dong Hyun Jo, Young Suk Yu
    Journal of Pediatric Hematology/Oncology.2018; 40(8): 569.     CrossRef
  • Diosmetin protects against retinal injury via reduction of DNA damage and oxidative stress
    Zeren Shen, Jinjin Shao, Jiabin Dai, Yuchen Lin, Xiaochun Yang, Jian Ma, Qiaojun He, Bo Yang, Ke Yao, Peihua Luo
    Toxicology Reports.2016; 3: 78.     CrossRef
  • Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma
    Seung Min Hahn, Hyo Sun Kim, Dong Joon Kim, Sung Chul Lee, Chuhl Joo Lyu, Jung Woo Han
    Pediatric Hematology and Oncology.2016; 33(1): 74.     CrossRef
  • Diagnosis & Treatment of Retinoblastoma: Current Review
    Heewon Chueh
    Clinical Pediatric Hematology-Oncology.2015; 22(1): 38.     CrossRef
  • High‐dose chemotherapy with autologous stem cell rescue for treatment of retinoblastoma: Report of five cases
    Désirée Caselli, Angela Tamburini, Agostino La Torre, Liliana Pollazzi, Veronica Tintori, Franco Bambi, Roberto Caputo, Maurizio Aricò
    Pediatric Transplantation.2014; 18(6): 631.     CrossRef
  • Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: preliminary results from 140 treatments
    Carlo Venturi, Sandra Bracco, Alfonso Cerase, Samuele Cioni, Paolo Galluzzi, Paola Gennari, Ignazio M. Vallone, Rebecca Tinturini, Cesare Vittori, Sonia De Francesco, Mauro Caini, Alfonso D’Ambrosio, Paolo Toti, Alessandra Renieri, Theodora Hadjistilianou
    Acta Ophthalmologica.2013; 91(4): 335.     CrossRef
  • Comparison of the diagnostic value of MR imaging and ophthalmoscopy for the staging of retinoblastoma
    Aman Khurana, Christina A. Eisenhut, Wenshuai Wan, Katayoon B. Ebrahimi, Chirag Patel, Joan M. O’Brien, Kristen Yeom, Heike E. Daldrup-Link
    European Radiology.2013; 23(5): 1271.     CrossRef
  • Anti-apoptotic effect of clusterin on cisplatin-induced cell death of retinoblastoma cells
    HYUN BEOM SONG, HYOUNG-OH JUN, JIN HYOUNG KIM, YOUNG SUK YU, KYU-WON KIM, BON HONG MIN, JEONG HUN KIM
    Oncology Reports.2013; 30(6): 2713.     CrossRef
  • Combined Treatment with an Oncolytic Adenovirus and Antitumor Activity of Vincristine against Retinoblastoma Cells
    Xin Song, Haibo Wang, Renbing Jia, Biyun Cun, Xiaoping Zhao, Yixiong Zhou, Xiaofang Xu, Guanxiang Qian, Shengfang Ge, Xianqun Fan
    International Journal of Molecular Sciences.2012; 13(9): 10736.     CrossRef
  • Long Term Follow-up Results of External Beam Radiotherapy as Primary Treatment for Retinoblastoma
    Sang Yul Choi, Mi-Sook Kim, SungYul Yoo, ChulKoo Cho, YoungHoon Ji, KumBae Kim, YoungSeok Seo, Kyung Duk Park, JunAh Lee, Tai-Won Lee
    Journal of Korean Medical Science.2010; 25(4): 546.     CrossRef
  • 12,338 View
  • 85 Download
  • 17 Crossref
Close layer
Initial Response to Treatment was Highly Associated with the Prognosis of Childhood Rhabdomyosarcoma: A Retrospective Analysis of a Single Center Experience in Korea
Jeong A Park, Eun Kyung Kim, Hyoung Jin Kang, Hee Young Shin, Il Han Kim, Hyo Seop Ahn
Cancer Res Treat. 2008;40(3):111-115.   Published online September 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.3.111
AbstractAbstract PDFPubReaderePub
Purpose

Following the introduction of a multimodal approach to diagnosis and treatment, the prognosis of rhabdomyosarcoma (RMS) has markedly improved over the last three decades. However, there are few data on treatment outcomes in Korean patients.

Materials and Methods

We performed a retrospective analysis of 77 patients with RMS diagnosed and treated at Seoul National University Children's Hospital between 1986 and 2005.

Results

The overall 5-year survival and event-free survival rates for all patients were 77% and 59%, respectively. The Intergroup Rhabdomyosarcoma Study clinical grouping and initial response to treatment (20-week response) were important prognostic factors.

Conclusions

The outcome of childhood RMS was closely associated with the initial staging and the initial response to treatment. Modulating therapies according to initial responses and risk factors is critical, and new treatment strategies for high-risk patients are needed.

Citations

Citations to this article as recorded by  
  • Adherence to Treatment, Response and Patterns of Failure in Pediatric Parameningeal Rhabdomyosarcoma: Experience From a Tertiary Cancer Care Center From India
    Soumyajit Roy, Sushmita Pathy, Bidhu K. Mohanti, Subhash Chander, Ahitagni Biswas
    Journal of Pediatric Hematology/Oncology.2017; 39(2): e62.     CrossRef
  • Pediatric rhabdomyosarcoma in India: A single-center experience
    Deepak Bansal, Anirban Das, Amita Trehan, Rakesh Kapoor, Naresh K. Panda, Radhika Srinivasan, Nandita Kakkar, Kushaljit S. Sodhi, Akshay K. Saxena, Katragadda Lakshmi Narasimha Rao
    Indian Pediatrics.2017; 54(9): 735.     CrossRef
  • The impact of radiotherapy on clinical outcomes in parameningeal rhabdomyosarcoma
    Yunseon Choi, Do Hoon Lim
    Radiation Oncology Journal.2016; 34(4): 290.     CrossRef
  • Rhabdomyosarcoma Treatment and Outcome at a Multidisciplinary Pediatric Cancer Center in Lebanon
    Maysaa Salman, Hani Tamim, Fouad Medlej, Tarek El-Ariss, Fatima Saad, Fouad Boulos, Toufic Eid, Samar Muwakkit, Nabil Khoury, Miguel Abboud, Raya Saab
    Pediatric Hematology and Oncology.2012; 29(4): 322.     CrossRef
  • Solid tumours of childhood
    Bruce O. Okoye
    Surgery (Oxford).2010; 28(8): 382.     CrossRef
  • Primary meningeal rhabdomyosarcoma associated with chronic subdural effusion
    Ji Yeoun Lee, Bo Sung Kim, Ji Hoon Phi, Hyoung Jin Kang, Sung-Hye Park, Kyu-Chang Wang, Il Han Kim, Byung-Kyu Cho, Seung-Ki Kim
    Journal of Neurosurgery: Pediatrics.2010; 5(2): 167.     CrossRef
  • 10,479 View
  • 38 Download
  • 6 Crossref
Close layer
Enhancement of Radiation Effects by Flavopiridol in Uterine Cervix Cancer Cells
Suzy Kim, Hong-Gyun Wu, Jin Hee Shin, Hye Jin Park, In Ah Kim, Il Han Kim
Cancer Res Treat. 2005;37(3):191-195.   Published online June 30, 2005
DOI: https://doi.org/10.4143/crt.2005.37.3.191
AbstractAbstract PDFPubReaderePub
Purpose

To determine the effects of combinations of radiation and flavopiridol, an inhibitor of cyclin-dependent kinases and global transcription, in a human uterine cervix cancer cell line.

Materials and Methods

Human uterine cervix cancer cells (HeLa), cultured to the mid-log phase, were exposed to X-rays, flavopiridol, and combinations of X-rays and flavopiridol in various sequences. The end point in this study was the clonogenic survival, which was measured via clonogenic assays. In order to determine the intrinsic cytotoxicity of flavopiridol, 0, 5, 12.5, 25, 37.5, 50 and 100 nM of flavopiridol were added to cell culture media. In the combination treatment, four different schedules of flavopiridol and irradiation combinations were tested: treatment of flavopiridol for 24 hours followed by irradiation, simultaneous administration of flavopiridol and irradiation, and irradiation followed by flavopiridol (for 24 hours) at intervals of 6 and 24 hours. The fraction of cells surviving after the combination treatment with 2 Gy of radiation (SF2) was compared with that of the fraction of cells surviving after treatment with irradiation alone.

Results

The cytotoxicity of flavopiridol was found to be dose-dependent, with an IC50 of 80 nM. No cytotoxic enhancements were observed when flavopiridol and radiation were administered simultaneously. Flavopiridol, administered either 24 hours before or 6 hours after irradiation, exerted no sensitizing effects on the cells. Only one protocol resulted in a radiosensitizing effect: the administration of flavopiridol 24 hours after irradiation.

Conclusion

Flavopiridol enhanced the effects of radiation on a uterine cervix cancer cell line in vitro, and this enhancement was both sequence- and time-dependent.

Citations

Citations to this article as recorded by  
  • Flavopiridol: a promising cyclin-dependent kinase inhibitor in cancer treatment
    Uttam Singh Baghel, Priyanka Kriplani, Neelam M. Patel, Manpreet Kaur, Kapil Sharma, Monika Meghani, Abhay Sharma, Deeksha Singh, Bhawani Singh, William N. Setzer, Javad Sharifi-Rad, Daniela Calina
    Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(4): 3489.     CrossRef
  • BAIRDA: a novel in vitro setup to quantify radiobiological parameters for cervical cancer brachytherapy dose estimations
    Braden Chow, Brad Warkentin, Kareena Nanda, Sunita Ghosh, Fleur Huang, Armin M Gamper, Geetha Menon
    Physics in Medicine & Biology.2022; 67(4): 045012.     CrossRef
  • Nutraceutical Compounds as Sensitizers for Cancer Treatment in Radiation Therapy
    Marco Calvaruso, Gaia Pucci, Rosa Musso, Valentina Bravatà, Francesco P. Cammarata, Giorgio Russo, Giusi I. Forte, Luigi Minafra
    International Journal of Molecular Sciences.2019; 20(21): 5267.     CrossRef
  • Repositioning disulfiram as a radiosensitizer against atypical teratoid/rhabdoid tumor
    Young Eun Lee, Seung Ah Choi, Pil Ae Kwack, Hak Jae Kim, Il Han Kim, Kyu-Chang Wang, Ji Hoon Phi, Ji Yeoun Lee, Sangjoon Chong, Sung-Hye Park, Kyung Duk Park, Do Won Hwang, Kyeung Min Joo, Seung-Ki Kim
    Neuro-Oncology.2017; 19(8): 1079.     CrossRef
  • Interaction of ω-3 polyunsaturated fatty acids with radiation therapy in two different colorectal cancer cell lines
    Fang Cai, Olivier Sorg, Virginie Granci, Elena Lecumberri, Raymond Miralbell, Yves M. Dupertuis, Claude Pichard
    Clinical Nutrition.2014; 33(1): 164.     CrossRef
  • Antitumor Effects of Flavopiridol on Human Uterine Leiomyoma In Vitro and in a Xenograft Model
    Hyun-Gyo Lee, Jong-Woo Baek, So-Jin Shin, Sang-Hoon Kwon, Soon-Do Cha, Won-Jin Park, Rosa Chung, Eun-Som Choi, Gun-Ho Lee, Chi-Heum Cho
    Reproductive Sciences.2014; 21(9): 1153.     CrossRef
  • In VitroRadiosensitization of Flavopiridol Did Not Translated intoIn VivoRadiosensitization
    Suzy Kim
    The Journal of the Korean Society for Therapeutic Radiology and Oncology.2011; 29(2): 83.     CrossRef
  • Gold Nanoparticles as Radiation Sensitizers in Cancer Therapy
    Devika B. Chithrani, Salomeh Jelveh, Farid Jalali, Monique van Prooijen, Christine Allen, Robert G. Bristow, Richard P. Hill, David A. Jaffray
    Radiation Research.2010; 173(6): 719.     CrossRef
  • 9,523 View
  • 51 Download
  • 8 Crossref
Close layer
A Histone Deacetylase Inhibitor, Trichostatin A, Enhances Radiosensitivity by Abrogating G2/M Arrest in Human Carcinoma Cells
In Ah Kim, Jin Ho Kim, Jin Hee Shin, Il Han Kim, Jae Sung Kim, Hong-Gyun Wu, Eui Kyu Chie, Yong Ho Kim, Bo-Kyung Kim, Semie Hong, Seok Won Park, Sung Whan Ha, Charn Il Park
Cancer Res Treat. 2005;37(2):122-128.   Published online April 30, 2005
DOI: https://doi.org/10.4143/crt.2005.37.2.122
AbstractAbstract PDFPubReaderePub
Purpose

Histone deacetylase inhibitors (HDIs) are emerging as potentially useful components in anticancer therapy. In this study, we tried to confirm the radiosensitizing effect of trichostatin A (TSA) on a panel of human carcinoma cell lines and elucidate its mechanism of interaction.

Materials and Methods

A549, HeLa and Caski cells were exposed to TSA for 18 hr prior to irradiation, and the cell survival then measured using a clonogenic assay. Western blot and flow cytometric analyses, for histone acetylation, and cell cycle and apoptosis, respectively, were also performed.

Results

TSA increased the acetylation of histone H3. The pretreatment of TSA consistently radiosensitized all three cell lines. The SF2 (surviving fraction at 2 Gy) of TSA-treated cells was significantly lower than that of mock treated cells. The SER (sensitizer enhancement ratio) increased in all 3 cell lines, in concentration dependent manners. The TSA treated cells showed abrogation of radiation-induced G2/M arrest, in a concentration dependent manner.

Conclusion

The pretreatment of TSA enhanced the radiosensitivity of a panel of human carcinoma cells, which was attributed, in part, to the abrogation of radiation-induced G2/M arrest.

Citations

Citations to this article as recorded by  
  • Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer
    Yijun Xie, Di Xiao, Duo Li, Mei Peng, Wei Peng, Huaxin Duan, Xiaoping Yang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Radiosensitizing effect of dendrosomal nanoformulation of curcumin on cancer cells
    Tahereh Jalali Varnamkhasti, Meisam Jafarzadeh, Majid Sadeghizadeh, Mahdi Aghili
    Pharmacological Reports.2022; 74(4): 718.     CrossRef
  • Pharmacological Properties of Trichostatin A, Focusing on the Anticancer Potential: A Comprehensive Review
    Abdelhakim Bouyahya, Nasreddine El Omari, Mohamed Bakha, Tarik Aanniz, Naoual El Menyiy, Naoufal El Hachlafi, Aicha El Baaboua, Mohamed El-Shazly, Mohammed Merae Alshahrani, Ahmed Abdullah Al Awadh, Learn-Han Lee, Taoufiq Benali, Mohammad S. Mubarak
    Pharmaceuticals.2022; 15(10): 1235.     CrossRef
  • Low Dose of Trichostatin A Improves Radiation Resistance by Activating Akt/Nrf2-Dependent Antioxidation Pathway in Cancer Cells
    Fengqiu Zhang, Changsheng Shao, Zhu Chen, Yalin Li, Xumiao Jing, Qing Huang
    Radiation Research.2021;[Epub]     CrossRef
  • Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
    Ying Li, Zhijun Zhan, Xuemin Yin, Shujun Fu, Xiyun Deng
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Is level of acetylation directly correlated to radiation sensitivity of cancer cell?
    Fengqiu Zhang, Zhu Chen, Changsheng Shao, Qing Huang
    Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis.2019; 813: 13.     CrossRef
  • Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53
    Manuela Terranova-Barberio, Biagio Pecori, Maria Serena Roca, Serena Imbimbo, Francesca Bruzzese, Alessandra Leone, Paolo Muto, Paolo Delrio, Antonio Avallone, Alfredo Budillon, Elena Di Gennaro
    Journal of Experimental & Clinical Cancer Research.2017;[Epub]     CrossRef
  • Histone Acetylation Induced Transformation of B-DNA to Z-DNA in Cells Probed through FT-IR Spectroscopy
    Fengqiu Zhang, Qing Huang, Jingwen Yan, Zhu Chen
    Analytical Chemistry.2016; 88(8): 4179.     CrossRef
  • Cell-based multi-substrate assay coupled to UHPLC-ESI-MS/MS for a quick identification of class-specific HDAC inhibitors
    Vincent Zwick, Claudia Simões-Pires, Muriel Cuendet
    Journal of Enzyme Inhibition and Medicinal Chemistry.2016; 31(sup1): 209.     CrossRef
  • Assessment of the Effect of Trichostatin A on HeLa Cells through FT-IR Spectroscopy
    Fengqiu Zhang, Qing Huang, Jingwen Yan, Xin Zhang, Jianxin Li
    Analytical Chemistry.2015; 87(4): 2511.     CrossRef
  • Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
    Ahrum Min, Seock-Ah Im, Debora Keunyoung Kim, Sang-Hyun Song, Hee-Jun Kim, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Mark J O’Connor, Yung-Jue Bang
    Breast Cancer Research.2015;[Epub]     CrossRef
  • CD44 is a biomarker associated with human prostate cancer radiation sensitivity
    WeiWei Xiao, Peter H. Graham, Carl A. Power, Jingli Hao, John H. Kearsley, Yong Li
    Clinical & Experimental Metastasis.2012; 29(1): 1.     CrossRef
  • Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells
    Han Sang Kim, Sang Cheol Kim, Sun Jeong Kim, Chan Hee Park, Hei-Cheul Jeung, Yong Bae Kim, Joong Bae Ahn, Hyun Cheol Chung, Sun Young Rha
    BMC Genomics.2012;[Epub]     CrossRef
  • In vivoRadiosensitization Effect of HDAC Inhibitor, SK-7041 on RIF-1 Cell Line
    Eui Kyu Chie, Jin Hee Shin, In Ah Kim, Il Han Kim
    The Journal of the Korean Society for Therapeutic Radiology and Oncology.2010; 28(4): 219.     CrossRef
  • Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: Potential role of histone deacetylase 6
    In Ah Kim, Mina No, Jang Mi Lee, Jin Hee Shin, Jee Sun Oh, Eun Jung Choi, Il Han Kim, Peter Atadja, Eric J. Bernhard
    Radiotherapy and Oncology.2009; 92(1): 125.     CrossRef
  • Histone Deacetylase Inhibitor–Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53
    In Ah Kim, Jin Hee Shin, Il Han Kim, Jin Ho Kim, Jae Sung Kim, Hong Gyun Wu, Eui Kyu Chie, Sung Whan Ha, Charn Il Park, Gary D. Kao
    Clinical Cancer Research.2006; 12(3): 940.     CrossRef
  • 12,673 View
  • 73 Download
  • 16 Crossref
Close layer
Outcome and Prognostic Factors of Childhood Diffuse Brainstem Glioma
Semie Hong, Il Han Kim, Kyu Chang Wang
Cancer Res Treat. 2005;37(2):109-113.   Published online April 30, 2005
DOI: https://doi.org/10.4143/crt.2005.37.2.109
AbstractAbstract PDFPubReaderePub
Purpose

The outcome and prognostic factors of brainstem glioma were evaluated following radiotherapy methods.

Materials and Methods

Between 1986 and 2001, 45 childhood patients with diffuse brainstem glioma were treated. There were 26 boys and 19 girls, with a median age of 7 years (range 3~18). The histopathological diagnoses were confirmed in 13 patients, which revealed a low-grade glioma in four patients, and high-grade glioma in the other nine. Before 1993, radiation therapy using a regime of 1.8 to 2.0 Gy once a day was performed in 16 cases; thereafter, a regimes of 1.1 or 1.5 Gy twice a day was given in 15 and 14 cases, respectively. Nine patients were treated with adjuvant chemotherapy. The response to the treatment was evaluated by the MRI findings 4 weeks after radiotherapy.

Results

After radiotherapy, the neurological deficit improved in 42 of the 45 patients (93%). The MRI responses were as follows; partial response 22/39 (56%), minimal to no response in 16/39 (41%) and tumor progression in 1/39 (3%). The median time to disease progression was 7 months, and the median survival was 12 months; the overall survival rate at 1 year was 41%. There was no significant prognostic factor for overall survival. The progression-free survival was influenced by the tumor histology (low grade vs. high grade, p=0.05) in those patients whose pathology was confirmed.

Conclusion

The radiation therapy fractionation schedule did not influence the survival. Low grade histology was a possible favorable prognostic factor of progression-free survival in pediatric brainstem glioma patients.

Citations

Citations to this article as recorded by  
  • Unveiling the Efficacy of Gamma Knife Radiosurgery for Tectal Plate Gliomas
    Nülifer Kilic Durankus, Yavuz Samanci, Ali Haluk Düzkalir, Selcuk Peker
    Neurosurgery.2024; 94(4): 780.     CrossRef
  • Deep learning based clinico-radiological model for paediatric brain tumor detection and subtype prediction
    Abhishek Mahajan, Mayur Burrewar, Ujjwal Agarwal, Bharadwaj Kss, Apparao Mlv, Amrita Guha, Arpita Sahu, Amit Choudhari, Vivek Pawar, Vivek Punia, Sridhar Epari, Ayushi Sahay, Tejpal Gupta, Girish Chinnaswamy, Prakash Shetty, Aliasgar Moiyadi
    Exploration of Targeted Anti-tumor Therapy.2023; : 669.     CrossRef
  • Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies
    Izac J. Findlay, Geoffry N. De Iuliis, Ryan J. Duchatel, Evangeline R. Jackson, Nicholas A. Vitanza, Jason E. Cain, Sebastian M. Waszak, Matthew D. Dun
    Oncogene.2022; 41(4): 461.     CrossRef
  • Clinical Efficacy of CyberKnife Radiosurgery for Adult Brainstem Glioma: 10 Years Experience at Tianjin CyberKnife Center and Review of the Literature
    Jiaqi Zhang, Qun Liu, Zhiyong Yuan, Lujun Zhao, Xiaoguang Wang, Ping Wang
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Radiotherapy for brainstem gliomas in children and adults: A single‐institution experience and literature review
    Kenji Yoshida, Nor Shazrina Sulaiman, Daisuke Miyawaki, Yasuo Ejima, Hideki Nishimura, Takeaki Ishihara, Yoshiro Matsuo, Ryo Nishikawa, Takashi Sasayama, Akira Hayakawa, Eiji Kohmura, Ryohei Sasaki
    Asia-Pacific Journal of Clinical Oncology.2017;[Epub]     CrossRef
  • Prognostic factors and survival in primary adult high grade brainstem astrocytoma: A population based study from 1973–2008
    Mahua Dey, Yimo Lin, Stephanie Melkonian, Sandi Lam
    Journal of Clinical Neuroscience.2014; 21(8): 1298.     CrossRef
  • A treatment planning comparison of highly conformal radiation therapy for pediatric low-grade brainstem gliomas
    Jeffrey V. Brower, Daniel J. Indelicato, Philipp R. Aldana, Eric Sandler, Ronny Rotondo, Nancy P. Mendenhall, Robert B. Marcus, Zhong Su
    Acta Oncologica.2013; 52(3): 594.     CrossRef
  • Stereotactic iodine-125 brachytherapy for treatment of inoperable focal brainstem gliomas of WHO grades I and II: feasibility and long-term outcome
    Maximilian I. Ruge, Philipp Kickingereder, Thorsten Simon, Harald Treuer, Volker Sturm
    Journal of Neuro-Oncology.2012; 109(2): 273.     CrossRef
  • 8,907 View
  • 74 Download
  • 8 Crossref
Close layer
Treatment Outcome of Brain Metastasis after the Cranial Radiotherapy Followed by Fractionated Stereotactic Radiotherapy and Its Prognostic Factors
Hak Jae Kim, Semie Hong, Suzy Kim, Jin Ho Kim, Il Han Kim, Charn Il Park, Sung Whan Ha, Hong Gyun Wu, Wee Saing Kang
Cancer Res Treat. 2002;34(4):284-288.   Published online August 31, 2002
DOI: https://doi.org/10.4143/crt.2002.34.4.284
AbstractAbstract PDF
To evaluate the effectiveness of whole brain radiotherapy followed by stereotactic radiotherapy for newly diagnosed brain metastasis.
MATERIALS AND METHODS
Thirty-three metastatic brain tumors received radiotherapy to the whole brain and stereotactic radiotherapy in 25 patients. Lung carcinomas were the most common (17/25) primary tumor. The radiation dose was 30 to 40 Gy for the whole brain, with a 12 to 40 Gy boost to the metastatic foci. Survival and local control rates were determined, and the prognostic factors for survival were evaluated.
RESULTS
The overall median survival was 15 months and the actuarial survivals at 1- and 2-year were 67% and 31%, respectively. The local tumor control rate was 79%, with a median follow-up period of 9 months (2~36 months). The prognostic factors associated with survival were age, tumor size and the existence of active extracranial metastasis, with the performance status showing marginal significance. No acute or chronic complications were observed in the patients.
CONCLUSION
From our data, cranial radiotherapy followed by stereotactic radiotherapy was useful in the local control of metastatic tumors, and in the survival of patients with tumor factors, such as small size or the absence of extracranial tumor activity, and host factors, such as young age or good performance status.

Citations

Citations to this article as recorded by  
  • Prognostic Factors and Survival Outcome of Whole Brain Radiotherapy in Metastatic Brain Cancer- A Single Regional Cancer Centre Experience in North India
    Purnima Thakur, Aman Sharma, Manish Gupta, Anupama Dhiman, Jyoti Sharma
    Journal of Evolution of Medical and Dental Sciences.2019; 8(43): 3206.     CrossRef
  • Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment
    Hee-Jun Kim, Seock-Ah Im, Bhumsuk Keam, Yu-Jung Kim, Sae-Won Han, Tae Min Kim, Do-Youn Oh, Jee Hyun Kim, Se-Hoon Lee, Eui Kyu Chie, Wonshik Han, Dong-Wan Kim, Tae-You Kim, Dong-Young Noh, Dae Seog Heo, In Ae Park, Yung-Jue Bang, Sung Whan Ha
    Journal of Neuro-Oncology.2012; 106(2): 303.     CrossRef
  • 4,162 View
  • 27 Download
  • 2 Crossref
Close layer
Usefulness of Change of Telomerase Activity as a Predictive Assay for Radiation Response
Hong Gyun Wu, Young Jue Kim, Il Han Kim, Charn Il Park, Sung Whan Ha
J Korean Cancer Assoc. 2000;32(6):1109-1114.
AbstractAbstract PDF
PURPOSE
A sensitive predictive assay is necessary to determine the total radiation dose according to sensitivity of individual cancer cell lines. This study is performed to determine whether the radiation sensitivity is correlated with the changes in telomerase activity after irradiation.
MATERIALS AND METHODS
Two colorectal cancer cell lines with different radiation sensitivity were used. In order to confirm the difference in radiation sensitivity, we used a calorimetric assay. Telomerase activities were measured using the PCR-based telomeric repeat amplification protocol (TRAP).
RESULTS
We confirmed the difference in radiation sensitivity between NCI-H630 and NCI-H716. Survival fractions at 2 Gy were 0.836 for NCI-H630 and 0.317 for NCI-H716. Telomerase activity increased after irradiation with NCI-H630, which was more resistant to radiation, whereas telomerase activity decreased with NCI-H730. But dose-dependent change of telomerase activity was not confirmed.
CONCLUSION
Our results suggested that telomerase activity change after irradiation could be used as a predictive assay for radiation response. Further studies with different cell lines and tumor tissues are necessary.
  • 2,299 View
  • 17 Download
Close layer
Efficacy and Optimal Condition of Radiotherapy for Metastatic Epidural Cord Compression
Il Han Kim, Suk Won Park, Eui Kyu Chie, Sung Whan Ha, Charn Il Park
J Korean Cancer Assoc. 1999;31(5):1074-1080.
AbstractAbstract PDF
PURPOSE
This study was performed to evaluate the radiotherapy effects on metastatic epidural cord compressions.
MATERIALS AND METHODS
One hundred and thirty eight cases received palliative radio- therapy (30 Gy/10 fractions) with (15) or without (123) surgical decompression. Only 36% of cases were ambulatory before treatment and 34% of cases started treatment within 3 days after symptom onset.
RESULTS
Ambulation was possible after radiotherapy in 38% of all patients and in 73% of cases who was ambulatory before treatment. But the treatment made ambulation possible for 18% of cases who was paraplegic before treatment. Complete response rate, partial response rate, minimal response rate, and progression after treatment were as follows; 7%, 37%, 53%, and 3% respectively for the motor function, 8%, 32%, 58%, and 2% respectively for the sensory function, and 17%, 17%, 65%, and 1% respectively for the autonomic function. Responses were not influenced by the primary tumor site, histology, or involved level of the spine. Good responses were associated with starting treatment within 3 days after symptom onset.
CONCLUSION
Radiotherapy gave optimal palliative effects on metastatic epidural cord compression syndrome. Maximum responses or quality of life could be obtained from prompt treatment with awareness of this syndrome in cancer patients.
  • 2,514 View
  • 12 Download
Close layer
Intracranial beta-hCG Secreting Germinoma: Clinical Significance and Radiotherapy Results
Kyung Hwan Shin, Il Han Kim, Wee Saing Kang, Sung Whan Ha, Charn Il Park
J Korean Cancer Assoc. 1999;31(2):396-402.
AbstractAbstract PDF
No abstract available.
  • 2,482 View
  • 16 Download
Close layer
Cancer Res Treat : Cancer Research and Treatment
© Korean Cancer Association.
Close layer
TOP